var title_f26_62_27616="Calculator: Venous segmental disease score for obstruction";
var content_f26_62_27616=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"VSDSObstruction_form\" name=\"VSDSObstruction_form\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Venous segmental disease score for obstruction",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"VSDSObstruction_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Great saphenous (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"VSDSObstruction_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Calf veins, multiple (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"VSDSObstruction_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Popliteal vein (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"VSDSObstruction_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Femoral vein (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"VSDSObstruction_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Deep femoral vein (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"VSDSObstruction_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Common femoral vein (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"VSDSObstruction_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Iliac vein (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"VSDSObstruction_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Inferior vena cava (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       To include the great saphenous, the thrombosis should extend below the knee.",
"      </li>",
"      <li>",
"       Obstruction due to excision, ligation, or trauma to deep venous segments counts in this score system.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Rutherford RB, Padberg FT Jr, Comerota AJ, et. al.  Venous severity scoring: An adjunct to venous outcome assessment.",
"        <i>",
"         J Vasc Surg",
"        </i>",
"        . 2000 Jun;31(6):1307-12.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"VSDSObstruction_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_62_27616=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function VSDSObstruction_fx() {",
"with(document.VSDSObstruction_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1.checked){",
"Score = Score + 1;",
"}",
"if (cc2.checked){",
"Score = Score + 1;",
"}",
"if (cc3.checked){",
"Score = Score + 2;",
"}",
"if (cc4.checked){",
"Score = Score + 1;",
"}",
"if (cc5.checked){",
"Score = Score + 1;",
"}",
"if (cc6.checked){",
"Score = Score + 2;",
"}",
"if (cc7.checked){",
"Score = Score + 1;",
"}",
"if (cc8.checked){",
"Score = Score + 1;",
"}",
"cctotal.value = Score;",
"}",
"}",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f26_62_27616=null;
var title_f26_62_27617="Healing deep partial thickness burn";
var content_f26_62_27617=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Healing deep partial thickness burn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 554px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These photographs show a deep, partial thickness burn of the proximal leg at different stages of healing. The top image was taken at one week, the middle image at four weeks, and bottom image at 10 months after the initial injury was sustained.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Simon G Talbot, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_62_27617=[""].join("\n");
var outline_f26_62_27617=null;
var title_f26_62_27618="Patient information: Probiotics (The Basics)";
var content_f26_62_27618=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/33/25105\">",
"         Patient information: Alternative medicine (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/47/28402\">",
"         Patient information: Antibiotic-associated diarrhea (C. difficile infection) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/56/22402\">",
"         Patient information: Bacterial vaginosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/1/14354\">",
"         Patient information: Vaginal yeast infection (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/38/40546\">",
"         Patient information: Vitamin supplements (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/52/19267\">",
"         Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/43/36529\">",
"         Patient information: Bacterial vaginosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/51/21300\">",
"         Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/29/39378\">",
"         Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/53/2899\">",
"         Patient information: Vaginal yeast infection (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Probiotics (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/probiotics-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H7863640\">",
"      <span class=\"h1\">",
"       What are probiotics?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probiotics are what many people call &ldquo;friendly bacteria&rdquo; or &ldquo;good bacteria.&rdquo; They are bacteria that live in the body and help it work well. Often probiotics help defend the body from infections caused by unfriendly bacteria or other germs.",
"     </p>",
"     <p>",
"      Probiotics get into your body on their own, so you can get benefits without doing or taking anything extra. But some people take pills that contain probiotics because they think the pills will help keep them healthy. Some people even take &ldquo;pre-biotics,&rdquo; which are pills that contain a form of food that probiotics like. The problem is, even though there is good proof that probiotics help the body, there is still no good proof that taking probiotic pills does any good.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7863655\">",
"      <span class=\"h1\">",
"       Do probiotic pills help improve health?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A few studies have hinted that probiotic pills might improve health, but scientists say there is not enough proof to say for sure. They think more research is needed.",
"     </p>",
"     <p>",
"      Right now, researchers are studying whether probiotics: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Can help fight or prevent infections in the stomach or intestines, including a serious infection called Clostridium difficile (also known as &ldquo;C diff&rdquo;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Can help with diarrhea, constipation, and some of the conditions that cause these symptoms, such as irritable bowel syndrome, ulcerative colitis, and Crohn&rsquo;s disease",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Prevent or treat allergies, including a skin condition called eczema, which makes the skin itchy and flaky",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Help prevent or fight infections in the vagina",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7863670\">",
"      <span class=\"h1\">",
"       Should I take probiotic pills?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. You should not take probiotics, unless your doctor or nurse tells you to. There is no proven benefit of taking probiotic pills.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7863685\">",
"      <span class=\"h1\">",
"       Should I eat yogurt with &ldquo;active cultures&rdquo;?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yogurt products that have &ldquo;active cultures&rdquo; have probiotics in them. If you like yogurt and can digest it normally, there is probably no harm in eating it. It&rsquo;s possible that eating yogurt will help your digestion and help keep you healthy. If nothing else, low-fat yogurt can be a part of a healthy diet.",
"     </p>",
"     <p>",
"      Some women put plain yogurt directly into their vagina to help prevent or treat infections in the vagina. Experts do not recommend doing this, because studies have not proven that it actually helps.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7863700\">",
"      <span class=\"h1\">",
"       What are the downsides to taking probiotics?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probiotics are not regulated by the Food and Drug Administration (the FDA) the way standard medicines are. That means that the companies that package probiotics don't have to prove that the ingredients listed on the label are actually in the bottle. In the end, you could buy a bottle that does not have what you think it has, so you could lose money. (Some probiotic pills are expensive.)",
"     </p>",
"     <p>",
"      Even if you do find pills that contain what you think they do, there&rsquo;s a small chance the pills could do you harm. Probiotics are seen as safe and &ldquo;friendly&rdquo; but they are still bacteria, which could, in theory, cause infections in people with weak immune systems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7863625\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/38/40546?source=see_link\">",
"       Patient information: Vitamin supplements (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/33/25105?source=see_link\">",
"       Patient information: Alternative medicine (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/47/28402?source=see_link\">",
"       Patient information: Antibiotic-associated diarrhea (C. difficile infection) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/1/14354?source=see_link\">",
"       Patient information: Vaginal yeast infection (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/56/22402?source=see_link\">",
"       Patient information: Bacterial vaginosis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/51/21300?source=see_link\">",
"       Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=see_link\">",
"       Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/52/19267?source=see_link\">",
"       Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/53/2899?source=see_link\">",
"       Patient information: Vaginal yeast infection (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/43/36529?source=see_link\">",
"       Patient information: Bacterial vaginosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/62/27618?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16894 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-D86B8ADF8C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_62_27618=[""].join("\n");
var outline_f26_62_27618=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7863640\">",
"      What are probiotics?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7863655\">",
"      Do probiotic pills help improve health?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7863670\">",
"      Should I take probiotic pills?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7863685\">",
"      Should I eat yogurt with &ldquo;active cultures&rdquo;?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7863700\">",
"      What are the downsides to taking probiotics?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7863625\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/33/25105?source=related_link\">",
"      Patient information: Alternative medicine (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/47/28402?source=related_link\">",
"      Patient information: Antibiotic-associated diarrhea (C. difficile infection) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/52/19267?source=related_link\">",
"      Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/43/36529?source=related_link\">",
"      Patient information: Bacterial vaginosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/56/22402?source=related_link\">",
"      Patient information: Bacterial vaginosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/51/21300?source=related_link\">",
"      Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=related_link\">",
"      Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/53/2899?source=related_link\">",
"      Patient information: Vaginal yeast infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/1/14354?source=related_link\">",
"      Patient information: Vaginal yeast infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/38/40546?source=related_link\">",
"      Patient information: Vitamin supplements (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_62_27619="Rubber band ligation";
var content_f26_62_27619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rubber band ligation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 563px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Figures A through E depict the technique of applying the rubber band to treat internal hemorrhoids.",
"    <br/>",
"    Figure A shows the forceps grasping the hemorrhoid. Note the band on the drum of the ligator.",
"    <br/>",
"    Figure B is a lateral view of the forceps grasping the hemorrhoid.",
"    <br/>",
"    Figure C shows the retraction of the forceps and the hemorrhoid into the drum of the ligator.",
"    <br/>",
"    Figure D shows the hemorrhoid pulled through the drum and the rubber band applied at the base of the hemorrhoid. Gentle traction is applied on the hemmorhoid by the forcep to secure it while the band is released from the ligator.",
"    <br/>",
"    Figure E depicts the banded, swollen hemorrhoid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_62_27619=[""].join("\n");
var outline_f26_62_27619=null;
var title_f26_62_27620="Atrial flutter RA recording";
var content_f26_62_27620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atrial flutter RA recording",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 177px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atrial flutter which is inapparent in lead I (upper panel); suggested by prominent negativity in lead II (arrows, middle panel), which could also represent biphasic T waves; and documented by right atrial recording, which shows prominent negative deflections (arrows, lower panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_62_27620=[""].join("\n");
var outline_f26_62_27620=null;
var title_f26_62_27621="Nipple and breast anatomy";
var content_f26_62_27621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nipple and breast anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ruan W, Kleinberg DL. Endocrinology 1999; 140:5075. Copyright &copy; 1999 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_62_27621=[""].join("\n");
var outline_f26_62_27621=null;
var title_f26_62_27622="Potassium phosphate: Drug information";
var content_f26_62_27622=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Potassium phosphate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/30/1508?source=see_link\">",
"    see \"Potassium phosphate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/58/4006?source=see_link\">",
"    see \"Potassium phosphate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neutra-Phos&reg;-K [OTC] [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F212083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Electrolyte Supplement, Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F212070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Caution: The concomitant amount of potassium must be calculated into the total electrolyte content. For each 1 mmol of phosphate, ~1.5 mEq of potassium will be administered. Therefore, if ordering 30 mmol of potassium phosphate, the patient will receive ~45 mEq of potassium. With orders for I.V. phosphate, there is considerable confusion associated with the use of millimoles (mmol) versus milliequivalents (mEq) to express the phosphate requirement.",
"     </b>",
"     The most reliable method of ordering I.V. phosphate is by millimoles, then specifying the potassium or sodium salt. Doses listed as mmol of phosphate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Acute treatment of  hypophosphatemia:",
"     </b>",
"     Repletion of severe hypophosphatemia should be done I.V. because large doses of oral phosphate may cause diarrhea and intestinal absorption may be unreliable. Reserve intermittent I.V. infusion for severe depletion situations; may require continuous cardiac monitoring depending on potassium administration rate. Guidelines differ based on degree of illness, need/use of parenteral nutrition, and severity of hypophosphatemia. If potassium &gt;4.0 mEq/L consider phosphate replacement strategy without potassium (eg, sodium phosphates). Patients with severe renal impairment were excluded from phosphate supplement trials.",
"     <b>",
"      Note:",
"     </b>",
"     1 mmol phosphate = 31 mg phosphorus; 1 mg phosphorus = 0.032 mmol phosphate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      General replacement guidelines",
"     </b>",
"     (Lentz, 1978):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Low dose, if serum phosphate losses are recent and uncomplicated: 0.08 mmol/kg over 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermediate dose, if serum phosphorus level 0.5-1 mg/dL (0.16-0.32 mmol/L): 0.16-0.24 mmol/kg over 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The initial dose may be increased by 25% to 50% if the patient is symptomatic secondary to hypophosphatemia and lowered by 25% to 50% if the patient is hypercalcemic.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Critically-ill adult patients receiving concurrent enteral/parenteral nutrition (Brown, 2006; Clark, 2006):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Round doses to the nearest 7.5 mmol for ease of preparation. If administering with phosphate-containing parenteral nutrition, do not exceed 15 mmol/L within parenteral nutrition. May use adjusted body weight for patients weighing &gt;130% of ideal body weight (and BMI&lt;40 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) by using [IBW + 0.25 (ABW-IBW)]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Low dose, serum phosphorus level 2.3-3 mg/dL (0.74-0.96 mmol/L): 0.16-0.32 mmol/kg over 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermediate dose, serum phosphorus level 1.6-2.2 mg/dL (0.51-0.71 mmol/L): 0.32-0.64 mmol/kg over 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     High dose, serum phosphorus &lt;1.5 mg/dL (&lt;0.5 mmol/L): 0.64-1 mmol/kg over 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Parenteral nutrition:",
"     </b>",
"     I.V.: 10-15 mmol/1000 kcal (Hicks, 2001)",
"     <b>",
"      or",
"     </b>",
"     20-40 mmol/24 hours (Mirtallo, 2004 [ASPEN guidelines])",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F212078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/58/4006?source=see_link\">",
"      see \"Potassium phosphate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Caution: The concomitant amount of potassium must be calculated into the total electrolyte content. For each 1 mmol of phosphate, ~1.5 mEq of potassium will be administered. Therefore, if ordering 30 mmol of potassium phosphate, the patient will receive ~45 mEq of potassium. With orders for I.V. phosphate, there is considerable confusion associated with the use of millimoles (mmol) versus milliequivalents (mEq) to express the phosphate requirement.",
"     </b>",
"     The most reliable method of ordering I.V. phosphate is by millimoles, then specifying the potassium or sodium salt. Doses listed as mmol of phosphate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Intermittent I.V. infusion should be reserved for severe depletion situations; may require continuous cardiac monitoring depending on potassium administration rate. It is difficult to determine total body phosphorus deficit. There are no prospective studies of parenteral phosphate replacement in children. The following weight-based guidelines for",
"     <b>",
"      adult",
"     </b>",
"     dosing may be cautiously employed in pediatric patients. Guidelines differ based on degree of illness, use of TPN, and severity of hypophosphatemia.",
"     <b>",
"      Note:",
"     </b>",
"     1 mmol phosphate = 31 mg phosphorus; 1 mg phosphorus = 0.032 mmol phosphate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      General replacement guidelines (Lentz, 1978):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Low dose, if serum phosphate losses are recent and uncomplicated: 0.08 mmol/kg over 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermediate dose, if serum phosphorus level 0.5-1 mg/dL (0.16-0.32 mmol/L): 0.16-0.24 mmol/kg over 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The initial dose may be increased by 25% to 50% if the patient is symptomatic secondary to hypophosphatemia and lowered by 25% to 50% if the patient is hypercalcemic.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Critically-ill adult patients receiving concurrent enteral/parenteral nutrition (Brown, 2006; Clark, 2006):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Round doses to the nearest 7.5 mmol for ease of preparation. If administering with phosphate-containing parenteral nutrition, do not exceed 15 mmol/L within parenteral nutrition. May use adjusted body weight for patients weighing &gt;130% of ideal body weight (and BMI&lt;40 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) by using [IBW + 0.25 (ABW-IBW)]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Low dose, serum phosphorus level 2.3-3 mg/dL (0.74-0.96 mmol/L): 0.16-0.32 mmol/kg over 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermediate dose, serum phosphorus level 1.6-2.2 mg/dL (0.51-0.71 mmol/L): 0.32-0.64 mmol/kg over 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     High dose, serum phosphorus &lt;1.5 mg/dL (&lt;0.5 mmol/L): 0.64-1 mmol/kg over 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Parenteral nutrition:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Infants and Children: 0.5-2 mmol/kg/24 hours (Mirtallo, 2004 [ASPEN guidelines])",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &gt;50 kg and Adolescents: 10-40 mmol/24 hours (Mirtallo, 2004 [ASPEN guidelines])",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F212071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F212056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: Potassium 4.4 mEq and phosphorus 3 mmol per mL (5 mL, 15 mL, 50 mL) [equivalent to potassium 170 mg and elemental phosphorus 93 mg per mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F212041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F212058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection must be diluted in appropriate I.V. solution and volume prior to administration. In general, the dose, concentration of infusion, and rate of administration may be dependent on patient condition and specific institution policy. Must consider administration precautions for phosphate and potassium when prescribing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     For adult patients with severe symptomatic hypophosphatemia (ie, &lt;1.5 mg/dL), may administer at rates up to 15 mmol phosphate/hour (this rate will deliver potassium at 22.5 mEq/hour) (Charron, 2003; Rosen, 1995). Potassium infusion rates &gt;10 mEq/hour should be administered via central line (minimizes burning and phlebitis). ECG monitoring is recommended for potassium infusions &gt;10 mEq/hour in adults or &gt;0.5 mEq/kg/hour in children. In patients with renal dysfunction and/or less severe hypophosphatemia, slower administration rates (eg, over 4-6 hours) or oral repletion is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Intermittent infusion doses of potassium phosphate are typically prepared in 100-250 mL of NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W (usual phosphate concentration range: 0.15 - 0.6 mmol/mL) (Charron, 2003; Rosen, 1995). Suggested maximum concentrations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Peripheral line administration: 6.7 mmoL potassium phosphate/100 mL (10 mEq potassium/100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Central line administration: 26.8 mmoL potassium phosphate/100 mL (40 mEq potassium/100 mL)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F212089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      10",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      10",
"     </sub>",
"     NS, LR;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Diltiazem, enalaprilat, esmolol, famotidine, labetalol, micafungin, nicardipine, nitroprusside, telavancin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amiodarone, caspofungin, ciprofloxacin, doripenem, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Drotrecogin alfa.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Aminophylline, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Magnesium sulfate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F212057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and prevention of hypophosphatemia;",
"     <b>",
"      Note:",
"     </b>",
"     The concomitant amount of potassium must be calculated into the total electrolyte content. For each 1 mmol of phosphate, ~1.5 mEq of potassium will be administered. Therefore, if ordering 30 mmol of potassium phosphate, the patient will receive ~45 mEq of potassium.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F212091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Per JCAHO recommendations, concentrated electrolyte solutions should not be available in patient care areas.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Consider special storage requirements for intravenous potassium salts; I.V. potassium salts have been administered IVP in error, leading to fatal outcomes.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Safe Prescribing: Because inorganic phosphate exists as monobasic and dibasic anions, with the mixture of valences dependent on pH, ordering by mEq amounts is unreliable and may lead to large dosing errors. In addition, I.V. phosphate is available in the sodium and potassium salt; therefore, the content of these cations must be considered when ordering phosphate. The most reliable method of ordering I.V. phosphate is by millimoles, then specifying the potassium or sodium salt. For example, an order for 15 mmol of phosphate as potassium phosphate in one liter of normal saline.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F212081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, bradycardia, chest pain, ECG changes, edema, heart block,  hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Listlessness, mental confusion, tetany (with large doses of phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, stomach pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urine output decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paralysis, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F212060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hyperphosphatemia, hyperkalemia, hypocalcemia, hypomagnesemia, renal failure (oral product)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F212044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Close monitoring of serum potassium concentrations is needed to avoid hyperkalemia; severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (eg, heart block, ventricular arrhythmias, asystole).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acid/base disorders: Use with caution in patients with acid/base alterations; changes in serum potassium concentrations can occur during acid/base correction, monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure, cardiac arrhythmias); patients may be more susceptible to life-threatening cardiac effects associated with hyper/hypokalemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; renal impairment requires close monitoring of serum potassium and phosphorus concentrations to avoid hyperkalemia and/or hyperphosphatemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Digoxin: Use with caution in digitalized patients; may be more susceptible to potentially life-threatening cardiac effects with rapid changes in serum potassium concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium-altering therapies: Use with caution in patients receiving concomitant medications or therapies that increase potassium (eg, ACEI, potassium-sparing diuretics, potassium containing salt substitutes).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Solutions for injection: May contain aluminum; toxic levels may occur following prolonged administration in premature neonates or patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium/phosphate compatibility: Admixture of phosphate and calcium in I.V. fluids can result in calcium phosphate precipitation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parenteral administration: Use extreme caution when administering potassium phosphate parenterally; evaluate patient's renal function, cardiac and fluid status, and any factors contributing to altered potassium concentrations (eg, acidosis, alkalosis) prior to therapy. Closely monitor potassium and phosphate concentrations and response to therapy. Parenteral potassium may cause pain and phlebitis, requiring a decrease in infusion rate or potassium concentration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F212049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: May enhance the hypocalcemic effect of Phosphate Supplements.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F212065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Avoid administering with oxalate (berries, nuts, chocolate, beans, celery, tomato) or phytate-containing foods (bran, whole wheat).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F212052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7828643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Phosphorus requirements are the same in pregnant and nonpregnant women (IOM, 1997). Although this product is not used for potassium supplementation, adverse events have not been observed following use of potassium supplements in healthy women with normal pregnancies. Use caution in pregnant women with other medical conditions (eg, pre-eclampsia; may be more likely to develop hyperkalemia) (IOM, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7828644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phosphorus, sodium, and potassium are normal constituents of human milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Neutra-Phos-K)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250-556 mg/75 mL (75 g): $15.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Potassium Phosphate Dibasic Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mmol/mL (5 mL): $1.22",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F212054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, calcium, phosphorus, magnesium (to facilitate potassium repletion); cardiac monitor (if intermittent infusion or potassium infusion rates 0.5 mEq/kg/hour in children or &gt;10 mEq/hour in adults); to assess adequate replacement, repeat serum potassium and phosphorus levels 2-4 hours after dose",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F13203038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Reference ranges may vary depending on the laboratory",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum calcium: 8.4-10.2 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum phosphorus: Both low and high ends of the normal range are higher in children than in adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants: 4.5-7.5 mg/dL (1.45-2.42 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: ~4-6 mg/dL (1.29-1.94 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 2.5-4.5 mg/dL (0.81-1.45 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum potassium: 3.5-5.2 mEq/L",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brown KA, Dickerson RN, Morgan LM, et al, &ldquo;A New Graduated Dosing Regimen for Phosphorus Replacement in Patients Receiving Nutrition Support,&rdquo;",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2006, 30(3):209-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/62/27622/abstract-text/16639067/pubmed\" id=\"16639067\" target=\"_blank\">",
"        16639067",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Charron T, Bernard F, Skrobik Y, et al, &ldquo;Intravenous Phosphate in the Intensive Care Unit: More Aggressive Repletion Regimens for Moderate and Severe Hypophosphatemia,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2003, 29(8):1273-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/62/27622/abstract-text/12845429/pubmed\" id=\"12845429\" target=\"_blank\">",
"        12845429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clark CL, Sacks GS, Dickerson RN, et al, &ldquo;Treatment of Hypophosphatemia in Patients Receiving Specialized Nutrition Support Using a Graduated Dosing Scheme: Results from a Prospective Clinical Trial,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1995, 23(9):1504-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/62/27622/abstract-text/7664552/pubmed\" id=\"7664552\" target=\"_blank\">",
"        7664552",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hicks W and Hardy G, &ldquo;Phosphate Supplementation for Hypophosphatemia and Parenteral Nutrition,&rdquo;",
"      <i>",
"       Curr Opin Clin Nutr Metab Care",
"      </i>",
"      , 2001, 4(3):227-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/62/27622/abstract-text/11517357/pubmed\" id=\"11517357\" target=\"_blank\">",
"        11517357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride",
"      </i>",
"      , National Academy of Sciences, Washington, DC, 1997.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate",
"      </i>",
"      , Washington, DC: National Academy Press, 2004.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joint Commission on Accreditation of Healthcare Organizations, &ldquo;2005 National Patient Safety Goals.&rdquo; Available at file://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/05_npsgs.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lentz RD, Brown DM, and Kjellstrand CM, &ldquo;Treatment of Severe Hypophosphatemia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1978, 89(6):941-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/62/27622/abstract-text/102230/pubmed\" id=\"102230\" target=\"_blank\">",
"        102230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirtallo J, Canada T, Johnson D, et al, &ldquo;Safe Practices for Parenteral Nutrition,&rdquo;",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2004, 28(6):S39-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/62/27622/abstract-text/15568296/pubmed\" id=\"15568296\" target=\"_blank\">",
"        15568296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perreault MM, Ostrop NJ, and Tierney MG, &ldquo;Efficacy and Safety of Intravenous Phosphate Replacement in Critically Ill Patients,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1997, 31(6):683-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/62/27622/abstract-text/9184705/pubmed\" id=\"9184705\" target=\"_blank\">",
"        9184705",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosen GH, Boullata JI, O'Rangers EA, et al, &ldquo;Intravenous Phosphate Repletion Regimen for Critically Ill Patients With Moderate Hypophosphatemia,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1995, 23(7):1204-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/62/27622/abstract-text/7600828/pubmed\" id=\"7600828\" target=\"_blank\">",
"        7600828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vannatta JB, Whang R, and Papper S, &ldquo;Efficacy of Intravenous Phosphorus Therapy in the Severely Hypophosphatemic Patient,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1981, 141(7):885-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/62/27622/abstract-text/7235807/pubmed\" id=\"7235807\" target=\"_blank\">",
"        7235807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9799 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9662981F41-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_62_27622=[""].join("\n");
var outline_f26_62_27622=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212067\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212083\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212070\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212078\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212071\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212056\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212041\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212058\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212089\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212057\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212091\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212081\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212060\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212044\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299925\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212049\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212065\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212052\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7828643\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7828644\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323717\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212054\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203038\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9799\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9799|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/30/1508?source=related_link\">",
"      Potassium phosphate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/58/4006?source=related_link\">",
"      Potassium phosphate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_62_27623="Pressure ulcers by stage";
var content_f26_62_27623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F67475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F67475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Pressure ulcers by stage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 526px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pressure ulcer staging.",
"    <br>",
"     (A) Stage I (erythema).",
"     <br>",
"      (B) Stage II (breakdown of dermis).",
"      <br>",
"       (C) Stage III (full-thickness skin breakdown).",
"       <br>",
"        (D) Stage IV (bone, muscle, and supporting tissue involved).",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         Reproduced with permission from: Nettina SM. The Lippincott manual of nursing practice, 7th ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_62_27623=[""].join("\n");
var outline_f26_62_27623=null;
var title_f26_62_27624="The humoral immune response";
var content_f26_62_27624=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The humoral immune response",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/62/27624/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/62/27624/contributors\">",
"     Francisco A Bonilla, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/62/27624/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/62/27624/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/62/27624/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/62/27624/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/62/27624/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"humoral\" refers to the non-cellular components of the blood, such as plasma and lymphatic fluid. The humoral immune response denotes immunologic responses that are mediated by antibodies. However, both B and T lymphocytes, as well as dendritic cells and other antigen presenting cells, are necessary for the formation of antigen-specific antibody.",
"   </p>",
"   <p>",
"    Humoral immunity includes the primary and secondary immune responses to antigen. During the primary immune response, an antigen is encountered by the host for the first time. Virgin B cells need to be activated and proliferate before an effective immune response can be generated. This primary response may be too slow to protect against many pathogens, therefore polyspecific natural antibodies with low affinity and the innate immune system may be utilized to limit microbial replication at the onset of infection. By comparison, the secondary antibody response, which results from the activation of a memory B cell, is faster and more effective in halting the progress of infection due to increased antibody binding affinities.",
"   </p>",
"   <p>",
"    Vaccination induces a primary immune response so that the patient produces the faster and more effective secondary response upon natural exposure to a pathogen, and is one of the most important contributions of immunology to disease prevention.",
"   </p>",
"   <p>",
"    An overview of the humoral immune response will be provided here. Discussions of immunoglobulin structure, function, and genetics, as well as a review of B cell development are found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=see_link\">",
"     \"Function and clinical applications of immunoglobulins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PASSIVE AND ACTIVE HUMORAL IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Passive humoral immunity is the acquisition of preformed antibodies from an external source, such as the administration of intramuscular or intravenous human immunoglobulin (Ig). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Passive immunity is naturally acquired during human gestation by the transplacental transfer of maternal IgG. IgA and IgM are not transported across the placenta, and the neonate has only small quantities of these isotypes in its circulation. After birth, the neonate continues to receive IgA passively via colostrum and breast milk, which affords local protection in the gut, with only minute quantities reaching the circulation. Maternal IgG from breast milk can reach the neonatal circulation through intestinal transepithelial Ig transport by the neonatal Fc receptor, FcRn, although the amount is very small relative to transplacental transfer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antibody levels in infancy and childhood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants develop the ability to respond to most antigenic challenges during the first few years of life. The figure shows the pattern of serum IgG levels in the first five years of life (",
"    <a class=\"graphic graphic_figure graphicRef73913 \" href=\"UTD.htm?31/25/32157\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgG &mdash; Maternal IgG in the infant is lost with a half life of 20 to 30 days, such that little maternal IgG or antibody is present by six months of age. The infant's own IgG rises gradually throughout the first year of life. These two changes occur simultaneously, resulting in a period from three to eight months of life during which the IgG levels are low. This is called physiologic hypogammaglobulinemia.",
"     </li>",
"     <li>",
"      IgM and IgA &mdash; Traces of IgM are synthesized by the infant. IgM levels increase rapidly during the first month of life, and then rise slowly thereafter to about 70 percent of adult levels by one year of age. IgA levels, generally absent at birth, gradually increase throughout the first year of life to about 30 percent of adult levels at one year. Adult levels of IgM and IgA are reached in adolescence [",
"      <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24570?source=see_link&amp;anchor=H2#H2\">",
"       \"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis\", section on 'Normal biology of IgA'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Active (or adaptive) immunity is the response generated during the encounter of the immune system with antigen. This may occur during the course of a natural infection, or after intentional antigen administration (vaccination).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANTIGEN DEPENDENT B CELL DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several distinct processes occur during the antigen-dependent phase of B cell development, including activation, proliferation, and differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/3\">",
"     3",
"    </a>",
"    ]. These are mentioned briefly here, and discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activation &mdash; The first distinct step in antigen-dependent B cell development is activation. Activation specifically refers to the resumption of the cell cycle, or the exit of the cell from its resting state.",
"     </li>",
"     <li>",
"      Proliferation &mdash; One of the consequences of activation is proliferation, during which the cells begin to divide. Proliferation is simply an increase in cell number without associated changes in the morphology or biochemistry of the cell.",
"     </li>",
"     <li>",
"      Differentiation &mdash; Differentiation refers to the changes occurring in B cells that determine development into memory cells or antibody producing plasma cells. The generation of many cells from one resting B cell is called clonal expansion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"       \"Immunoglobulin genetics\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ACTIVATION SIGNALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;B cells require two signals to become activated and begin differentiating into memory or plasma cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cross-linking of Ig receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first signal (often called signal 1) may be delivered via cross-linking of the Ig receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/5\">",
"     5",
"    </a>",
"    ]. Most soluble protein and glycoprotein antigens are monovalent and cannot cross-link Ig receptors alone; however, Ig receptor cross-linking may not be required in all responses to TD antigens, even though the degree to which it occurs may affect the quality of the immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, Ig receptor cross-linking is important in responses to type 2 antigens with many repeating determinants, which do not require cognate T cell help. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Types of antigens'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Low-affinity interactions with multispecific natural antibody can form immune complexes that may also contain complement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/7\">",
"     7",
"    </a>",
"    ]. These complexes could cross-link Ig receptors and also provide a second signal to B cells via CD21 (ie, the C3d complement fragment receptor). CD21 lowers the threshold for B cell activation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/8\">",
"     8",
"    </a>",
"    ]. Immune complexes could also be trapped on the surfaces of IgG Fc receptor-bearing cells, such as dendritic cells in various lymphoid tissues (spleen, lymph node, Peyer's patches). These cell-bound complexes might be even more effective at aggregating B cell Ig receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As described below, the second signal (signal 2) may be derived from cytokine(s) or from other cell surface interactions in different circumstances depending largely on the type of antigen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TYPES OF ANTIGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the context of the humoral immune response, antigens capable of activating B cells may be categorized into three groups [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thymus-independent type 1",
"     </li>",
"     <li>",
"      Thymus-independent type 2",
"     </li>",
"     <li>",
"      Thymus-dependent (TD) antigens",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first two groups are often referred to simply as type 1 or type 2 antigens. These types of antigens give rise to relatively low affinity antibody responses. IgM often predominates, although other isotypes (IgG, IgA) may also be produced. Immunologic memory is often weak or short-lived. In contrast, TD antigens tend to lead to the generation of higher affinity antibodies and lasting immunologic memory.",
"   </p>",
"   <p>",
"    Although these categories of antigens serve as convenient descriptive labels when discussing mechanisms of B cell activation, they should not be considered restrictive or mutually exclusive. An antigen may behave as type 1, type 2, or TD depending upon its chemical state, associated molecules, or the dose.",
"   </p>",
"   <p>",
"    These designations are derived principally from studies of antibody responses in mice. In humans, T cell participation appears to be more consistently required in the responses to most antigens, although the nature of the signals required varies with the type of antigen. The classification is also useful because of the different ways these molecules may interact with B cells directly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Type 1 antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 antigens are molecules of microbial or vegetal origin that bind to B cells and stimulate their proliferation and differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/12\">",
"     12",
"    </a>",
"    ]. These substances are polyclonal activators, or",
"    <strong>",
"     mitogens",
"    </strong>",
"    , since they stimulate B cells independent of their antigen specificity.",
"   </p>",
"   <p>",
"    B cell mitogens are usually polymers containing a repeating structural unit. Many are polysaccharides or lectins, proteins that agglutinate cells or precipitate certain macromolecules. The receptor(s) responsible for the mitogenic effect in many instances are not known. A potent mitogen for human B cells is Staphylococcus aureus Cowan strain (SAC). The bacterial protein A aggregates surface Ig receptors. Another human B cell mitogen is a plant lectin called pokeweed mitogen (PWM).",
"   </p>",
"   <p>",
"    At low concentrations, B cell mitogens stimulate specific antibody responses (ie, only antibodies which bind the mitogen are produced). At higher concentrations, mitogens induce B cell proliferation independent of antigen specificity. The action of mitogens on human B cells appears to require some participation of T cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/12\">",
"     12",
"    </a>",
"    ]. The mitogen may induce early stages in activation, rendering a B cell receptive to additional stimulatory signals provided by T cells.",
"   </p>",
"   <p>",
"    Epstein-Barr virus (EBV) has unique properties as an antigen because it is able to transform some B cells (ie, render them malignant) independent of the usual regulatory factors, including T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. The EBV receptor [also called CD21 or complement receptor 2 (CR2)], is the receptor for the complement fragment and B cell growth factor C3d. Transformation by EBV enables B cells to become antibody-secreting cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=see_link\">",
"     \"Virology of Epstein-Barr virus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=see_link\">",
"     \"Regulators and receptors of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Type 2 antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2 antigens elicit predominantly antigen-specific antibody responses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/11\">",
"     11",
"    </a>",
"    ]. Many type 2 antigens are similar to type 1 antigens in having repeating structures. Certain plant and bacterial polysaccharides are good examples. The Streptococcus pneumoniae capsular polysaccharide is a clinically important type 2 antigen. These antigens are able to cross-link specific immunoglobulin receptors on B cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neonatal B cells are poorly responsive to type 2 antigens, a fact that limits the utility of polysaccharide vaccines in young children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link\">",
"     \"Assessing the immunologic response to vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surface Ig cross-linking alone (in most cases) is not sufficient to induce B cell proliferation and differentiation, although it renders B cells receptive to T cell signals (cytokines) that further stimulate their progression toward antibody-secreting cells. In this setting, T helper cells do",
"    <strong>",
"     not",
"    </strong>",
"    need to make physical contact with B cells. This is referred to as",
"    <strong>",
"     non-cognate T cell help",
"    </strong>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     TACI, BAFF and APRIL",
"    </span>",
"    &nbsp;&mdash;&nbsp;One mechanism for activation and isotype switching is mediated by two B cell receptors: transmembrane activator and calcium-modulator and cytophilic ligand interactor (TACI) and B cell&ndash;activating factor of the TNF family Receptor (BAFF-R). The ligands, B cell&ndash;activating factor of the TNF family (BAFF) and A proliferation&ndash;inducing ligand (APRIL), can bind and stimulate both receptors resulting in isotype switch recombination [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/14\">",
"     14",
"    </a>",
"    ]. This receptor appears to be essential for antibody responses to Type 2 antigens, based on murine TACI knockout models [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/15\">",
"     15",
"    </a>",
"    ]. Furthermore, some patients with common variable immune deficiency (CVID) have been recognized to carry mutations in TACI, although the significance of this finding has been a source of ongoing controversy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Additional activating signals",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibody binding to the Ig receptor: As may be expected, anti-Ig antibodies activate B cells regardless of their antigen specificity. This activation requires cross-linking of surface Ig, since monovalent anti-Ig Fab fragments are not activating, while divalent F(ab)'2 fragments are. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7318?source=see_link\">",
"       \"Structure of immunoglobulins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antibody directed against one of several B cell surface molecules (such as the Ig receptors themselves or class II histocompatibility molecules) binds to that molecule: Antibodies binding various surface molecules, such as CD20, CD21, and CD22, may have modulatory effects on B cell activation, in combination with other signals [",
"      <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Binding of toll-like receptors (TLRs) on B cells by ligand can activate B cells in isolation or synergistically with other signals: An important example is unmethylated CpG DNA which binds to TLR9 and is present in bacterial genomes. This ligand can induce activation and isotype switching in B cells [",
"      <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     TD antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of protein and glycoprotein antigens encountered by the immune system are TD antigens. Antibody production requires close collaboration between T and B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With antibody responses to TD antigens, two types of cellular interaction are required:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first, T cells recognize antigen associated with histocompatibility molecules on the surface of an antigen presenting cell. After the T cell is activated, it becomes capable of providing help to a B cell for antibody production (ie, it becomes a T helper, or Th \"effector\" cell).",
"     </li>",
"     <li>",
"      The second interaction is between a B cell and the Th cell. Via the Ig receptor, B cells internalize antigen; it is then processed and associated with MHC class II molecules, as with any antigen presenting cell. This action is necessary for a Th cell to be able to recognize the appropriate B cells to which it will deliver its stimulating signals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cognate T cell help",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second signal for B cell activation is delivered via intimate membrane contacts with a T helper cell, which is sometimes called cognate T cell help [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/20\">",
"     20",
"    </a>",
"    ]. This interaction involves a variety of receptors and ligands expressed by both cells. Several of these surface proteins are known as adhesion molecules since they facilitate intimate cellular contact. Many of these also have important roles in initiating and propagating stimulatory biochemical mechanisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     CD40 and CD40 ligand",
"    </span>",
"    &nbsp;&mdash;&nbsp;One very important pathway of activation involves the interaction between a pair of molecules, CD40 on the B cell, and CD154 (also called CD40 ligand or CD40L) on an activated T cell [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/21\">",
"     21",
"    </a>",
"    ]. Binding CD40 on the B cell is critical for the processes of immunoglobulin class-switching, antibody affinity maturation, and formation of memory B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Defects in CD154 lead to the X-linked hyper-IgM syndrome, a form of severe immune deficiency characterized, in part, by a relative inability of B cells to switch from IgM to IgG or IgA production [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/23\">",
"     23",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/32/21001?source=see_link\">",
"     \"Hyperimmunoglobulin M syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although all of the different activating signals for B cell proliferation and differentiation are not yet known, it is clear that several mechanisms operate in concert, and that more than one type of signal is required. As already discussed, for example, cross-linking of surface Ig receptors constitutes one type of B cell activation signal. However, in the absence of additional signals, the B cell will not become activated. In fact, Ig receptor cross-linking without further stimuli renders B cells anergic, ie, unable to respond to activating signals delivered in the future. This may be an important mechanism of B cell tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once a sufficient set of activating signals are received, the B cell then begins to differentiate into either a plasma cell or a memory cell.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Immune complexes and Fc regions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune complexes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Ig Fc regions have been shown either to activate or suppress B cells independently of antigen, or stimulate or inhibit specific antigen responses. The variable responses that result depend upon the character of the immune complexes",
"    <span class=\"nowrap\">",
"     (antigen/antibody",
"    </span>",
"    ratio), the timing of administration (before, with, or after antigen), and the isotype of the antibodies in the complex (IgG versus IgM) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antigen-specific antibodies administered passively with antigen may suppress immune responses by masking the antigen and interfering with its recognition (binding) by B cells, or by interfering with T-B cell cooperation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/26\">",
"     26",
"    </a>",
"    ]. In some experiments, however, passively administered antibodies can enhance antigen-specific responses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/26\">",
"     26",
"    </a>",
"    ]. This may occur by forming stimulating immune complexes, or by enhancing antigen uptake by Fc receptors of antigen presenting cells.",
"   </p>",
"   <p>",
"    Some forms of immune complexes may be suppressive for B cells. As an example, the simultaneous cross-linking of the Ig receptor and the Fc receptor FcgRII (CD32) on B cells suppresses B cell activation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=see_link\">",
"     \"Neutrophil functions other than movement\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CELLULAR EVENTS IN B CELL ACTIVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several pathways by which resting B cells become activated and begin proliferating, as discussed previously. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Activation signals'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Activating events",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, resting B cells may be activated by the following events:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Binding of type 1 antigens (mitogens) to mitogen receptors",
"     </li>",
"     <li>",
"      Binding of type 2 antigens to Ig receptors",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      to mitogen receptors followed by T helper cell-derived cytokines",
"     </li>",
"     <li>",
"      Ig receptor cross-linking by antigen complexed on follicular dendritic cells and appropriate MHC-determined interactions with activated Th cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, B cells may receive an activating signal through Fc receptors, complement receptors (eg, CD21, the C3d receptor CR2), class II histocompatibility molecules, or by cross-linking surface Ig with anti-Ig antibodies. In most cases, some T cell-derived signals (cytokines) are required to initiate or complete proliferation and differentiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Intracellular signaling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous intracellular signaling pathways in lymphocytes (B and T) are regulated via tyrosine, serine, or threonine phosphorylation of one or more components of the pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/28\">",
"     28",
"    </a>",
"    ]. Protein kinases (PTKs) and phosphatases, respectively, phosphorylate and dephosphorylate their various substrates. Phosphorylation (or dephosphorylation) of the intracellular domain of a membrane protein enables its association with other signal-transducing molecules. Some important B cell surface molecules that may be reversibly tyrosine-phosphorylated include the Ig-alpha and -beta components of the Ig receptor, CD19 and CD22. Phosphorylation of these molecules permits their association with other kinases or adapter proteins, and initiates activation. Many kinases and phosphatases are themselves substrates of other kinases and phosphatases, and are regulated by phosphorylation. Detailed reviews of the multitude of intracellular signaling pathways in B cell activation have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     GERMINAL CENTERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Germinal centers (GCs) are the areas within lymph nodes and the spleen in which B cell maturation occurs and the cellular events responsible for immunologic memory take place. Within GCs, B cells develop into plasma cells capable of producing high-affinity antibodies, or into memory B cells devoted to transporting the \"experience\" of the immune system around the body and permitting more rapid antibody production when the same antigen is encountered in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Within the peripheral lymphoid tissues, B cells that have not yet been exposed to antigen form spherical collections of cells called primary lymphoid follicles. These primary follicles contain follicular dendritic cells (FDC), interspersed with small resting B cells. The FDC present antigen-antibody complexes on their surface, which stimulate B cell growth and differentiation. In the first days after exposure to antigen in T-dependent immune responses (through vaccination, for example), B cell activation begins outside of lymphoid follicles. In one model, interdigitating cells, Th cells, and B cells were shown to interact in the marginal zones of the spleen.",
"   </p>",
"   <p>",
"    The primary lymphoid follicle then becomes populated with a small number (three, on average) of B cells that will give rise to all of the progeny cells of that GC. The pre-existing resting B cells are pushed to the periphery of the follicle to form the follicular mantle. The incoming B cells have already received some combination of activating signals from antigen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T cells in the periphery prior to their arrival in the newly-forming GC. These cells are able to take up and process antigen from the follicular cell surface. They then present it to Th cells, which deliver further activating signals and drive development. The germinal center is thus made up of activated and proliferating B cells, FDC, as well as a small number of T cells and macrophages. The GC with its surrounding resting B cells is called a secondary lymphoid follicle.",
"   </p>",
"   <p>",
"    B cell differentiation within GC is highly regulated and compartmentalized. B cells migrate to one end of the lymphoid follicle to form the dark zone of the germinal center, where they become centroblasts (",
"    <a class=\"graphic graphic_figure graphicRef77980 \" href=\"UTD.htm?24/40/25216\">",
"     figure 2",
"    </a>",
"    ). These centroblasts continue to divide and give rise to centrocytes that migrate to the basal light zone. Somatic mutation of Ig V genes then takes place during cell division and selection of centrocytes. If they are able to interact with antigen, they migrate to the apical light zone; if not, they die (",
"    <a class=\"graphic graphic_figure graphicRef57024 \" href=\"UTD.htm?17/28/17871\">",
"     figure 3",
"    </a>",
"    ). The cells with receptors having the highest affinity for antigen have a selective advantage and will dominate the response [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/29\">",
"     29",
"    </a>",
"    ]. Three possible fates are hypothesized for B cells surviving to enter the apical light zone of the germinal center: terminal differentiation to plasma cells; terminal differentiation to memory cells; or reentry to the dark zone to undergo further division and mutation.",
"   </p>",
"   <p>",
"    Two signals are important for ensuring the survival of B cells within germinal centers: one is the cross-linking of Ig receptors by antigen complexed on FDC; the other is the interaction of B cell CD40 with its ligand CD154 on a T cell (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Cognate T cell help'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The CD40 signal is critical for driving somatic mutation and class-switching. Somatic mutation followed by selection based upon antibody affinity leads to the increased affinity seen in ongoing antibody responses and in the memory response. Class-switching permits the production of antibodies displaying a diverse array of effector mechanisms, such as neutralization, complement fixation, etc. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=see_link\">",
"     \"Function and clinical applications of immunoglobulins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     IMMUNOLOGIC MEMORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immune response in a person that has never before encountered a given antigen is called a primary immune response, as discussed previously. The immune response in a person that has at least one prior exposure to the antigen is called a secondary immune response.",
"   </p>",
"   <p>",
"    Following antigen exposure, there is a lag period before antibody is detectable. This period corresponds to the cellular events in the activation, proliferation, and differentiation of B cells to antibody-secreting cells.",
"   </p>",
"   <p>",
"    Primary and secondary responses differ with respect to the lag period, the magnitude and duration of the response, and the isotypes and affinity of antibodies produced (",
"    <a class=\"graphic graphic_figure graphicRef71886 \" href=\"UTD.htm?16/61/17374\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. The actual duration of the lag period and the speed with which antibodies are then produced varies, depending on the dose of antigen, route of administration, and whether the antigen persists in the body or is cleared.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Primary immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the primary response to a TD antigen, there is a logarithmic increase in serum IgM antibodies from 4 to 10 days. This increase reflects clonal expansion and antibody production. Clonal expansion is associated with Ig class-switching so that the proportion of IgG (and other isotypes) increases with time. Somatic mutation also occurs, producing antibodies of higher affinity later in the response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Na&iuml;ve B cells that have not yet encountered antigen express IgM and IgD on their surface, but are negative for CD27, a receptor that is important in T cell costimulation. Thus, these naive B cells are CD27-IgM+IgD+.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Affinity maturation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each cycle of division within a germinal center leads to selection of cells having the receptors with the highest affinity for antigen. This phenomenon is called affinity maturation. Thus, the secondary antibody repertoire, established after an encounter of the immune system with antigen, consists of clones derived from the primary (virgin B cell) repertoire that have been expanded via a diversification process of somatic mutation with selection for cells with high affinity for antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As antigen is cleared from the body, the immune response gradually wanes. Persistence of antigen leads to ongoing antibody production. Some antigens are capable of inducing long-lasting antibody production, even after they are cleared (eg, measles virus). The mechanism for this is not known. Such antigens may persist in particular sites, allowing continued stimulation of B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/39\">",
"     39",
"    </a>",
"    ]. Alternatively, these antigens may stimulate the development of particularly long-lived antibody-producing cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Secondary immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The memory B cell, or plasma cell, is the hallmark of acquired humoral immunity. Memory is generated predominantly for T-dependent antigens, although it can also be obtained with type 2 antigens. Memory B cells are morphologically similar to small resting lymphocytes. They usually display IgG, IgA, or IgE on their surface, although some have IgM. They generally lack IgD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Memory B cells can be identified by the presence of CD27. Memory B cells can be subdivided into those cells that have not yet undergone isotype switching and produce predominantly IgM (CD27+IgM+IgD+), and those that have isotype switched (CD27+IgM-IgD-) and synthesize IgG, IgM, or IgA. Defects in these stages of maturation can result in immunodeficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=see_link\">",
"     \"Pathogenesis of common variable immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Memory cells circulate actively from blood to lymph and survive for much longer periods of time between mitoses (years or decades). They preferentially populate mucosal areas where they are more likely to come into contact with foreign antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/34\">",
"     34",
"    </a>",
"    ]. Memory cells are thought to constitute only about 1 percent of the total B cell population. Memory B cells disappear after 10 to 12 weeks without continued antigenic stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/42\">",
"     42",
"    </a>",
"    ]. However, many persist for longer periods due to continued antigenic stimulation and they can be very long-lived, surviving for several decades.",
"   </p>",
"   <p>",
"    The secondary humoral response is characterized by a much shorter lag period, and the rapid production of isotypes other than IgM (",
"    <a class=\"graphic graphic_figure graphicRef71886 \" href=\"UTD.htm?16/61/17374\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. These rapidly appearing IgG, A, or E molecules have high affinity for antigen and are derived from memory cells developed in the primary response. By virtue of their Ig receptors' high affinity for antigen, memory cells are stimulated by much lower antigen concentrations than are virgin B cells. In addition, memory cells are more efficient at antigen presentation and are more receptive to T cell help [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/43\">",
"     43",
"    </a>",
"    ]. In some cases, memory cells may not require T cells for activation.",
"   </p>",
"   <p>",
"    Memory cells which proliferate outside of germinal centers do not undergo any further somatic mutation in their Ig V genes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/44\">",
"     44",
"    </a>",
"    ]. Some cells may reenter germinal centers where they may undergo further rounds of somatic mutation and antigen selection for higher affinity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27624/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The humoral immune response denotes immunologic responses that are mediated by antibodies. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction and definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonates rely heavily upon maternal IgG, passed through the placenta, and IgA transferred through colostrum and breast milk. After infancy, the child's immunoglobulins gradually increase as levels of maternal antibodies wane (",
"      <a class=\"graphic graphic_figure graphicRef73913 \" href=\"UTD.htm?31/25/32157\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antibody levels in infancy and childhood'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibodies are produced when B cells encounter antigen and respond by undergoing activation, proliferation, and differentiation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Antigen dependent B cell development'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antigens may be categorized as type I (mitogens), type 2 (antigens which stimulate specific B cells and generate specific antibody production), and T cell dependent antigens (TD antigens, or antigens which require extensive interaction between B and T cells to generate antibodies). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Types of antigens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      B cells require two signals to become activated and begin differentiating into memory or plasma cells. The first is cross-linking of their surface Ig receptors, and the second is cognate T cell help, which refers to activating interactions between B and T cells via one of several receptor-ligand pairs. If both activating signals are not received, the B cell may respond with anergy to that antigen. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Activation signals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Germinal centers are the areas within lymph nodes and the spleen in which B cell maturation occurs and the cellular events responsible for immunologic memory take place (",
"      <a class=\"graphic graphic_figure graphicRef77980 \" href=\"UTD.htm?24/40/25216\">",
"       figure 2",
"      </a>",
"      ). Within germinal centers, B cells develop into plasma cells capable of producing high-affinity antibodies, as well as into memory B cells devoted to monitoring the body for subsequent exposures to the same antigen. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Germinal centers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once antigen enters the body and interacts with the immune system, there is an initial lag period during which B cells become activated and then proliferate and differentiate into antibody-producing plasma cells. The primary immune response has a relatively long lag (usually between 4 and 10 days), and results in the production of mostly IgM. Memory B cells are also produced during the primary immune response. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Primary immune response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Memory B cells may live for many years, circulating around the body (particularly mucosal surfaces) in search of antigen. Upon encountering antigen, they rapidly begin to produce specific antibody. The secondary immune response has a shorter lag period and results in the production of greater amounts of IgG (or sometimes IgA or IgE) antibodies, with higher antigen affinity compared to those made in the primary immune response. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Secondary immune response'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/1\">",
"      Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/2\">",
"      Jolliff CR, Cost KM, Stivrins PC, et al. Reference intervals for serum IgG, IgA, IgM, C3, and C4 as determined by rate nephelometry. Clin Chem 1982; 28:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/3\">",
"      McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu Rev Immunol 2005; 23:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/4\">",
"      Baumgarth N. A two-phase model of B-cell activation. Immunol Rev 2000; 176:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/5\">",
"      Clark EA, Lane PJ. Regulation of human B-cell activation and adhesion. Annu Rev Immunol 1991; 9:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/6\">",
"      Cruchley AT, Williams DM, Niedobitek G, Young LS. Epstein-Barr virus: biology and disease. Oral Dis 1997; 3 Suppl 1:S156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/7\">",
"      Thornton BP, Vtvicka V, Ross GD. Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes. J Immunol 1994; 152:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/8\">",
"      Tedder TF, Zhou LJ, Engel P. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol Today 1994; 15:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/9\">",
"      Kosco-Vilbois MH, Gray D, Scheidegger D, Julius M. Follicular dendritic cells help resting B cells to become effective antigen-presenting cells: induction of B7/BB1 and upregulation of major histocompatibility complex class II molecules. J Exp Med 1993; 178:2055.",
"     </a>",
"    </li>",
"    <li>",
"     Coutinho A, Gronowicz E, Moller G. Activation of lymphocytes by antigen and mitogen. In: Regulation of growth and differentiated function in eukaryote cells, Talwar GP (Ed), Raven Press, New York 1975. p.213.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/11\">",
"      Vos Q, Lees A, Wu ZQ, et al. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev 2000; 176:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/12\">",
"      Richards S, Watanabe C, Santos L, et al. Regulation of B-cell entry into the cell cycle. Immunol Rev 2008; 224:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/13\">",
"      K&uuml;ppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003; 3:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/14\">",
"      Castigli E, Wilson SA, Scott S, et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 2005; 201:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/15\">",
"      von B&uuml;low GU, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity 2001; 14:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/16\">",
"      Castigli E, Wilson SA, Garibyan L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005; 37:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/17\">",
"      Salzer U, Chapel HM, Webster AD, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005; 37:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/18\">",
"      Peng SL. Signaling in B cells via Toll-like receptors. Curr Opin Immunol 2005; 17:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/19\">",
"      Huggins J, Pellegrin T, Felgar RE, et al. CpG DNA activation and plasma-cell differentiation of CD27- naive human B cells. Blood 2007; 109:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/20\">",
"      Mills DM, Cambier JC. B lymphocyte activation during cognate interactions with CD4+ T lymphocytes: molecular dynamics and immunologic consequences. Semin Immunol 2003; 15:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/21\">",
"      Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004; 22:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/22\">",
"      Grammer AC, Slota R, Fischer R, et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003; 112:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/23\">",
"      Ferrari S, Plebani A. Cross-talk between CD40 and CD40L: lessons from primary immune deficiencies. Curr Opin Allergy Clin Immunol 2002; 2:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/24\">",
"      Fulcher DA, Basten A. B-cell activation versus tolerance--the central role of immunoglobulin receptor engagement and T-cell help. Int Rev Immunol 1997; 15:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/25\">",
"      Morgan EL, Hobbs MV, Thoman MT, Weigle WO. Lymphocyte activation by the Fc region of immunoglobulins. Immunol Invest 1986; 15:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/26\">",
"      Pincus CS, Nussenzweig V. Passive antibody may simultaneously suppress and stimulate antibody formation against different portions of a protein molecule. Nature 1969; 222:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/27\">",
"      Chacko GW, Tridandapani S, Damen JE, et al. Negative signaling in B lymphocytes induces tyrosine phosphorylation of the 145-kDa inositol polyphosphate 5-phosphatase, SHIP. J Immunol 1996; 157:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/28\">",
"      Kurosaki T. Regulation of B-cell signal transduction by adaptor proteins. Nat Rev Immunol 2002; 2:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/29\">",
"      Rajewsky K. Clonal selection and learning in the antibody system. Nature 1996; 381:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/30\">",
"      MacLennan IC. Germinal centers. Annu Rev Immunol 1994; 12:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/31\">",
"      Allen CD, Okada T, Cyster JG. Germinal-center organization and cellular dynamics. Immunity 2007; 27:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/32\">",
"      McKendall RR, Pettit M, Woo W. The immunoglobulin response to individual HSV-1 viral polypeptides: kinetics of the response during primary and secondary experimental infection with herpes simplex virus. J Med Microbiol 1988; 25:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/33\">",
"      Gysin J, Fandeur T, Pereira da Silva L. Kinetics of the humoral immune response to blood-induced falciparum malaria in the squirrel monkey Saimiri sciureus. Ann Immunol (Paris) 1982; 133D:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/34\">",
"      Welliver RC, Kaul TN, Putnam TI, et al. The antibody response to primary and secondary infection with respiratory syncytial virus: kinetics of class-specific responses. J Pediatr 1980; 96:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/35\">",
"      Tangye SG, Avery DT, Deenick EK, Hodgkin PD. Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses. J Immunol 2003; 170:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/36\">",
"      Foote J, Milstein C. Kinetic maturation of an immune response. Nature 1991; 352:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/37\">",
"      Berek C, Milstein C. The dynamic nature of the antibody repertoire. Immunol Rev 1988; 105:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/38\">",
"      Allen D, Cumano A, Dildrop R, et al. Timing, genetic requirements and functional consequences of somatic hypermutation during B-cell development. Immunol Rev 1987; 96:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/39\">",
"      Gatto D, Martin SW, Bessa J, et al. Regulation of memory antibody levels: the role of persisting antigen versus plasma cell life span. J Immunol 2007; 178:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/40\">",
"      Gray D, Bergthorsdottir S, van Essen D, et al. Observations on memory B-cell development. Semin Immunol 1997; 9:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/41\">",
"      Lane P. Development of B-cell memory and effector function. Curr Opin Immunol 1996; 8:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/42\">",
"      Gray D, Skarvall H. B-cell memory is short-lived in the absence of antigen. Nature 1988; 336:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/43\">",
"      Liu YJ, Barth&eacute;l&eacute;my C, de Bouteiller O, et al. Memory B cells from human tonsils colonize mucosal epithelium and directly present antigen to T cells by rapid up-regulation of B7-1 and B7-2. Immunity 1995; 2:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27624/abstract/44\">",
"      Liu YJ, Zhang J, Lane PJ, et al. Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur J Immunol 1991; 21:2951.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3975 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-3AAB480B33-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_62_27624=[""].join("\n");
var outline_f26_62_27624=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PASSIVE AND ACTIVE HUMORAL IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antibody levels in infancy and childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANTIGEN DEPENDENT B CELL DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ACTIVATION SIGNALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cross-linking of Ig receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TYPES OF ANTIGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Type 1 antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Type 2 antigens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - TACI, BAFF and APRIL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Additional activating signals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TD antigens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cognate T cell help",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - CD40 and CD40 ligand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Immune complexes and Fc regions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CELLULAR EVENTS IN B CELL ACTIVATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Activating events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Intracellular signaling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      GERMINAL CENTERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      IMMUNOLOGIC MEMORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Primary immune response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Affinity maturation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Secondary immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3975\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3975|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/25/32157\" title=\"figure 1\">",
"      Serum IgG levels less than 5 y",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/40/25216\" title=\"figure 2\">",
"      Germinal center",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/28/17871\" title=\"figure 3\">",
"      B cell dev in germ centers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/61/17374\" title=\"figure 4\">",
"      Primary and second responses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=related_link\">",
"      Assessing the immunologic response to vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=related_link\">",
"      Function and clinical applications of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/32/21001?source=related_link\">",
"      Hyperimmunoglobulin M syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=related_link\">",
"      Neutrophil functions other than movement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=related_link\">",
"      Pathogenesis of common variable immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=related_link\">",
"      Regulators and receptors of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24570?source=related_link\">",
"      Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7318?source=related_link\">",
"      Structure of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=related_link\">",
"      Virology of Epstein-Barr virus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_62_27625="Epidemiology, clinical manifestations, and diagnosis of psoriasis";
var content_f26_62_27625=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/62/27625/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/62/27625/contributors\">",
"     Steven R Feldman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/62/27625/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/62/27625/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/62/27625/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/62/27625/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/62/27625/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriasis is a common chronic skin disorder typically characterized by erythematous papules and plaques with a silver scale, although other presentations occur. Most cases are not severe enough to affect general health and are treated in the outpatient setting. Rare life-threatening presentations can occur that require intensive inpatient management.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, and diagnosis of psoriatic skin disease will be reviewed here. The pathophysiology and treatment of psoriatic skin disease and issues related to psoriatic arthritis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/45/729?source=see_link\">",
"     \"Pathophysiology of psoriasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link\">",
"     \"Treatment of psoriasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40234?source=see_link\">",
"     \"Treatment of psoriatic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23608?source=see_link\">",
"     \"Pathogenesis of psoriatic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=see_link\">",
"     \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide psoriasis prevalence rates range from 0.6 percent to 4.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/1\">",
"     1",
"    </a>",
"    ]. A population-based study in the United States estimated that the prevalence of psoriasis was 2.5 percent in Caucasians and 1.3 percent in African-Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psoriasis affects men and women equally [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/3\">",
"     3",
"    </a>",
"    ], and is seen in all races. Although psoriasis can begin at any age, there seem to be two peaks in onset: one between ages 20 and 30 and another between 50 and 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective study of a cohort of adults reported an increased incidence of psoriasis between the years 1970 to 1974 (50.8 cases per 100,000) and 1995 to 1999 (100.5 cases per 100,000) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/5\">",
"     5",
"    </a>",
"    ]. Another cohort study assessing the incidence of psoriasis in children also reported increasing incidence, from 29.6 cases per 100,000 to 62.7 cases per 100,000 during the same time periods [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/6\">",
"     6",
"    </a>",
"    ]. These studies suggest that psoriasis incidence or diagnosis might be increasing, although few other studies report on incidence to confirm this finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although genetic predisposition clearly plays a role in the development of psoriasis (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Genetic factors'",
"    </a>",
"    below), environmental and behavioral factors frequently affect the course of disease. Numerous potential \"triggers\" for psoriasis have been identified, such as infection, physical or psychological stress, and medications; however, they are not common to every patient.",
"   </p>",
"   <p>",
"    Patients with psoriasis tend to show improvement in summer months, likely due to greater exposure to ultraviolet radiation from sunlight and perhaps to increased relative humidity.",
"   </p>",
"   <p>",
"    Smoking is associated with an increased risk of psoriasis and also with increased severity of psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. The Nurses' Health Study, which prospectively evaluated the risk for incident psoriasis in 78,532 women, found an increased risk with greater intensity of smoking, and gradual reduction in risk after quitting smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/11\">",
"     11",
"    </a>",
"    ]. These results suggest a causal relationship where smoking actually increases the risk of psoriasis. Palmoplantar pustulosis, which is considered by some to be a localized variant of pustular psoriasis, is strongly associated with smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    A number of other lifestyle factors may have a relation to psoriasis. Psoriasis has been associated with obesity and higher body mass index (BMI) in adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/14-19\">",
"     14-19",
"    </a>",
"    ]. While it has traditionally been thought that obesity was a result of unhealthy behavior patterns in patients with psoriasis, results from the Nurses&rsquo; Health Study suggest that obesity may contribute to the development of more severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/16\">",
"     16",
"    </a>",
"    ]. Increased levels of proinflammatory cytokines, including TNF-alpha, in tissue or serum in obese patients may contribute to the relationship between psoriasis and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/17\">",
"     17",
"    </a>",
"    ]. Alcohol consumption is also associated with psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin D deficiency may be associated with increased risk for certain autoimmune diseases, including type 1 diabetes, multiple sclerosis, and inflammatory bowel disease (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31193?source=see_link&amp;anchor=H651669#H651669\">",
"     \"Vitamin D and extraskeletal health\", section on 'Immune system'",
"    </a>",
"    ). The role of vitamin D status in psoriasis is uncertain. A case-control study that compared 43 patients with psoriasis and 43 matched controls with other non-photosensitive dermatologic diseases found that serum levels of 25-hydroxyvitamin D were significantly lower in the patients with psoriasis even after adjusting for factors such as Fitzpatrick skin phototype (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 1",
"    </a>",
"    ) and estimated sun exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/22\">",
"     22",
"    </a>",
"    ]. Further studies are necessary to explore the relationship between psoriasis and vitamin D deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, the understanding of the pathogenesis of psoriasis has reflected the treatments available at the time. Where previously psoriasis had been viewed as primarily a disease of hyperproliferation, more recently it has come to be regarded as an immune-mediated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. It appears that psoriasis is a complex immune-mediated disease in which T-lymphocytes and dendritic cells play a central role. The role of the immune system in psoriasis is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/45/729?source=see_link\">",
"     \"Pathophysiology of psoriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The typical clinical findings of erythema and scaling are the result of hyperproliferation and abnormal differentiation of the epidermis, plus inflammatory cell infiltrates and vascular changes. This hyperproliferative state, when compared with normal epidermis, is characterized by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased numbers of epidermal stem cells",
"     </li>",
"     <li>",
"      Increased numbers of cells undergoing DNA synthesis",
"     </li>",
"     <li>",
"      A shortened cell cycle time for keratinocytes (36 hours compared with 311 hours in normal skin)",
"     </li>",
"     <li>",
"      A decreased turnover time of the epidermis (four days from basal cell layer to stratum corneum, compared with 27 days in normal skin)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abnormal differentiation in psoriatic skin is evidenced by a delay in the expression of keratins 1 and 10 (seen in normal skin) and an overexpression of keratins 6 and 16 (seen in reactive and healing skin).",
"   </p>",
"   <p>",
"    The body of evidence demonstrating the importance of the immune system in the pathogenesis of psoriasis is contributing to the development of new therapies for the disease. Much of the current research in psoriasis treatment focuses on immune modulation. The use of systemic agents (\"biologics\") that work though targeted interference with leukocytes and cytokines is revolutionizing psoriasis therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/45/729?source=see_link\">",
"     \"Pathophysiology of psoriasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H36#H36\">",
"     \"Treatment of psoriasis\", section on 'Biologic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriasis has long been known to occur in families. The possible role of genetic factors can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 40 percent of patients with psoriasis or psoriatic arthritis have a family history of these disorders in first degree relatives [",
"      <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Family studies in psoriatic arthritis have demonstrated that the disease is 100 times more likely to occur among family members than among unrelated controls.",
"     </li>",
"     <li>",
"      Psoriasis tends to be concordant among monozygotic twins more commonly than among dizygotic twins [",
"      <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genome-wide association studies have identified multiple susceptibility loci for psoriasis, many of which contain genes involved in regulation of the immune system [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. The psoriasis-susceptibility (PSORS1) locus within the major histocompatibility complex (MHC) on chromosome 6p21 (location of the HLA genes) is considered the major genetic determinant of psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Among other MHC genes that have been associated with psoriasis, HLA-Cw6 is the most important allele for susceptibility to early-onset psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. HLA-B17 may be associated with a more severe phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MHC and HLA associations explain only a portion of genetic susceptibility to psoriasis. IL-12 and IL-23 have been implicated in the pathogenesis of psoriasis and are targets for drug development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/45/729?source=see_link&amp;anchor=H12219645#H12219645\">",
"     \"Pathophysiology of psoriasis\", section on 'Interleukin-23'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/45/729?source=see_link&amp;anchor=H12219659#H12219659\">",
"     \"Pathophysiology of psoriasis\", section on 'Interleukin-12'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several single nucleotide polymorphisms (SNP) in the shared subunit of the receptor for IL-12 and IL-23 have been linked to psoriasis and other chronic inflammatory conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Certain receptor polymorphisms appear to predispose to, or protect from, psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In addition, the IL12B gene, which encodes the p40 subunit of IL-12 and IL-23, as well as the IL23A gene, which encodes the p19 subunit of IL-23, are strongly associated with psoriasis.",
"   </p>",
"   <p>",
"    <br/>",
"    Additional examples of genes involved in immune regulation that are linked to psoriasis include TNIP1 and TNFAIP3, whose gene products act downstream of TNF-alpha and regulate NF-B signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/39\">",
"     39",
"    </a>",
"    ]. Genes encoding IL-4 and IL-13, which modulate Th2 responses, and beta defensins, which are involved in innate immunity, are also implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the LCE gene cluster on chromosome 1q21, which encodes cornified envelope proteins that are important for epidermal cell differentiation, is a susceptibility locus for psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/41\">",
"     41",
"    </a>",
"    ]. A genome-wide scan revealed that deletions of LCE3B and LCE3C, genes located within the LCE cluster, are associated with an increased risk of psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27414545\">",
"    <span class=\"h2\">",
"     Generalized pustular psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A linkage analysis study of familial cases of generalized pustular psoriasis that identified a homozygous missense mutation in the IL36RN gene has provided additional information on the pathogenesis of psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/43\">",
"     43",
"    </a>",
"    ]. IL36RN is responsible for the production of the IL-36 receptor antagonist (IL-36Ra), an antiinflammatory cytokine that inhibits inflammation by preventing the binding of IL-36 to its receptor, thereby inhibiting the activation of NF-B and mitogen activated protein (MAP) proinflammatory signal pathways.",
"   </p>",
"   <p>",
"    The presence of a defect in IL-36Ra function in patients with inherited generalized pustular psoriasis strongly suggests that abnormalities in this pathway contribute to the development of this inflammatory disease. The in vitro observation that stimulation by proinflammatory cytokines led to much higher production of IL-8 (a proinflammatory cytokine) in keratinocytes with the IL36RN mutation than in keratinocytes from controls offers additional support for the importance of this pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It remains unclear whether these findings apply to forms of psoriasis other than generalized pustular disease. Since the simultaneous occurrence of generalized pustular psoriasis and lesions consistent with psoriasis vulgaris is not uncommon, it is possible that other variants of psoriasis may share this pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriasis can usually be recognized with ease, but atypical or non-classic forms are more difficult to identify and treat. Several clinical types of psoriasis have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Plaque psoriasis",
"     </li>",
"     <li>",
"      Guttate psoriasis",
"     </li>",
"     <li>",
"      Pustular psoriasis",
"     </li>",
"     <li>",
"      Inverse psoriasis",
"     </li>",
"     <li>",
"      Nail psoriasis",
"     </li>",
"     <li>",
"      Erythrodermic psoriasis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, psoriasis may occur more frequently and become more severe in certain populations, such as those with HIV infection. A number of individuals with psoriasis also develop psoriatic arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=see_link\">",
"     \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Psoriasis is a rare cause of mortality (eg, with widespread pustular or erythrodermic psoriasis), but there are at least hundreds of deaths in the United States annually [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition to mortality from severe disease, some deaths may be due to adverse effects from systemic therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Plaque psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plaque psoriasis is the most common variant of psoriasis. One population-based study found that plaque psoriasis accounted for approximately 80 percent of cases of psoriasis in adults and approximately 75 percent of cases of psoriasis in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients with plaque type psoriasis usually present as young adults with symmetrically distributed plaques involving the scalp, extensor elbows, knees, and back. The plaques are erythematous with sharply defined margins that are raised above the surrounding normal skin (",
"    <a class=\"graphic graphic_picture graphicRef81412 \" href=\"UTD.htm?39/55/40831\">",
"     picture 1",
"    </a>",
"    ). A thick silvery scale is usually present, although recent bathing may remove the scale. The lesions can range from less than 1 to more than 10 cm in diameter. The plaques typically are asymptomatic, although some patients complain of pruritus. Close inspection may reveal pitting of the nail plates and involvement of intertriginous areas such as the umbilicus and intergluteal cleft.",
"   </p>",
"   <p>",
"    Psoriasis can also commonly involve the external ear canal. The clinical appearance is generally similar to other forms of psoriasis, with redness and scaling. Seborrheic dermatitis (dandruff) can cause similar changes in the ear and may be present at the same time as an entity referred to as \"sebo-psoriasis\". Differentiating the two for treatment purposes is not essential, as the treatment of seborrheic dermatitis is similar. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of psoriasis\", section on 'Corticosteroids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Guttate psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guttate psoriasis refers to the abrupt appearance of multiple small psoriatic lesions. It is distinct from chronic plaque psoriasis that presents with primarily small plaques. Guttate psoriasis typically occurs as an acute eruption in a child or young adult with no previous history of psoriasis. Less commonly, a guttate psoriatic flare occurs in a patient with preexisting psoriasis.",
"   </p>",
"   <p>",
"    The lesions in guttate psoriasis are usually less than 1 cm in diameter (giving rise to the name guttate, which means drop-like). They primarily involve the trunk (",
"    <a class=\"graphic graphic_picture graphicRef55141 graphicRef64836 \" href=\"UTD.htm?34/34/35368\">",
"     picture 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A strong association exists between recent streptococcal infection, usually pharyngitis, and guttate psoriasis. In one study, for example, serologic evidence of recent streptococcal infection was present in 19 of 33 patients (58 percent) with acute guttate psoriasis and 7 of 27 patients (26 percent) with guttate exacerbations of chronic psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/45\">",
"     45",
"    </a>",
"    ]. This association was not serotype specific; while Streptococcus pyogenes was a common isolate, other beta-hemolytic streptococci were found with equal frequency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Inverse psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Inverse psoriasis\" refers to a presentation involving the intertriginous areas, including the inguinal, perineal, genital, intergluteal, axillary, and inframammary regions (",
"    <a class=\"graphic graphic_picture graphicRef79274 graphicRef76200 graphicRef78531 graphicRef50615 graphicRef62411 \" href=\"UTD.htm?40/41/41626\">",
"     picture 3A-E",
"    </a>",
"    ). This presentation is called \"inverse\" since it is the reverse of the typical presentation on extensor surfaces. This variant can easily be misdiagnosed as a fungal or bacterial infection since there is frequently no visible scaling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nail psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact prevalence of nail changes in psoriasis is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/46\">",
"     46",
"    </a>",
"    ]. It is estimated that nail changes occur in up to half of patients with psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Nail involvement may be the only manifestation of psoriasis in 1 to 5 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of nail disease may be important diagnostically, often providing valuable supportive evidence of disease in difficult cases. Nail disease is more common in patients with psoriatic arthritis, a finding that may be related to close proximity of the distal interphalangeal joints and the nail matrix. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of psoriatic arthritis\", section on 'Nail lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of nail psoriasis are related to involvement of the nail matrix or nail bed. The typical nail abnormality associated with matrix disease is pitting, consisting of a few to multiple tiny pits scattered over the nail plate (",
"    <a class=\"graphic graphic_picture graphicRef70962 \" href=\"UTD.htm?15/7/15474\">",
"     picture 4",
"    </a>",
"    ). These changes produce friable areas of cornified nail plate that erode away with normal friction.",
"   </p>",
"   <p>",
"    When the nail bed is involved, a localized color change in the nail may occur that resembles the tan-brown color of new motor oil, the \"oil drop sign\" (",
"    <a class=\"graphic graphic_picture graphicRef66374 \" href=\"UTD.htm?32/51/33585\">",
"     picture 5",
"    </a>",
"    ). Subungual hyperkeratosis represents more severe nail involvement, and results in thick crumbling nails that can be confused with onychomycosis (",
"    <a class=\"graphic graphic_picture graphicRef53509 \" href=\"UTD.htm?28/29/29138\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Psoriatic nails are refractory to most topical treatments and typically require systemic therapy or subungual injections of glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link\">",
"     \"Treatment of psoriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pustular psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pustular psoriasis can be a severe form of psoriasis with life-threatening complications (",
"    <a class=\"graphic graphic_picture graphicRef75707 \" href=\"UTD.htm?13/8/13454\">",
"     picture 7",
"    </a>",
"    ). The acute onset of widespread erythema, scaling, and sheets of superficial pustules with erosions characterizes the most severe variant of pustular psoriasis (the von Zumbusch variant). This form can be associated with malaise, fever, diarrhea, leukocytosis, and hypocalcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=see_link&amp;anchor=H22#H22\">",
"     \"Neutrophilic dermatoses\", section on 'Generalized pustular psoriasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hepatic abnormalities associated with pustular psoriasis have been demonstrated. In a report of 22 consecutive patients, 20 (90 percent) had at least one abnormal liver biochemical test while one-half had pronounced abnormalities including jaundice, elevated aminotransferase (up to three times the upper limit of normal) and alkaline phosphatase levels (higher than twice the upper limit of normal) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/49\">",
"     49",
"    </a>",
"    ]. Two patients underwent liver biopsies that revealed neutrophilic cholangitis. Liver biochemical abnormalities normalized with treatment, although some patients were left with persistent cholangiographic features resembling sclerosing cholangitis.",
"   </p>",
"   <p>",
"    There are several less severe or localized variants of pustular psoriasis, most notably palmoplantar pustulosis. This type usually occurs in adults and consists of tender pustules on the palms and soles, often with painful fissuring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=see_link&amp;anchor=H22#H22\">",
"     \"Neutrophilic dermatoses\", section on 'Generalized pustular psoriasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reported causes of pustular psoriasis include pregnancy, infection, and the withdrawal of oral glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Erythrodermic psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrodermic psoriasis is an uncommon manifestation that may be acute or chronic. It is characterized by generalized erythema and scaling from head to toe (",
"    <a class=\"graphic graphic_picture graphicRef71225 \" href=\"UTD.htm?27/0/27654\">",
"     picture 8",
"    </a>",
"    ). Such patients are at high risk for complications related to loss of adequate barrier protection such as infection (including sepsis) and electrolyte abnormalities secondary to fluid loss [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/50\">",
"     50",
"    </a>",
"    ]. Inpatient management involving a dermatologist is frequently necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2637210\">",
"    <span class=\"h2\">",
"     Ocular findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders of the eye, such as blepharitis, conjunctivitis, xerosis, corneal lesions, and uveitis may occur with increased frequency in patients with psoriasis. Symptoms of eye involvement include ocular discomfort, flaking or crusting within the eyelashes, swollen eyelids, red eyes, visual changes, and psoriatic lesions on the lids or lid margins [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proportion of patients with psoriasis and ocular disorders is not definitively known, and guidelines for screening for ocular involvement in patients with psoriasis have not been established. Asking patients about ocular symptoms at each follow-up visit may help to identify patients with ocular involvement. In addition, some authors have suggested routine ophthalmic examinations every one to two years in patients with severe psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Psoriasis in HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriasis may be the presenting sign of HIV infection, or it can develop after the diagnosis has been made. Psoriasis associated with HIV infection frequently is severe, with palmar and plantar involvement, nail disease, arthritis, and widespread nearly erythrodermic disease. Considerable overlap between HIV-associated psoriasis, psoriatic arthritis with HLA-B27 positivity, and reactive arthritis has led several authors to view these entities as a disease continuum [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=see_link\">",
"     \"Pathogenesis of spondyloarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Psoriatic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriatic arthritis is one of several seronegative spondyloarthropathies that include ankylosing spondylitis and reactive arthritis. It is seen in less than one-third of patients with psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. Most patients have coincidental skin involvement, although arthritis precedes the skin disease in approximately 15 percent of cases, and skin lesions are present but have not been diagnosed in an additional 15 percent. Nail involvement is often severe, but there is no direct relationship between the severity of skin and joint involvement in psoriasis. Enthesitis (inflammation at the site of tendon insertion into bone) at the Achilles tendon insertion on the calcaneus is a common site for pain in patients with psoriatic arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=see_link\">",
"     \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several clinical patterns of joint involvement in psoriatic arthritis have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/57\">",
"     57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distal arthritis, characterized by involvement of the distal interphalangeal (DIP) joints (",
"      <a class=\"graphic graphic_picture graphicRef70503 \" href=\"UTD.htm?15/39/15999\">",
"       picture 9",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Asymmetric oligoarthritis in which less than five small",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      large joints are affected in an asymmetric distribution.",
"     </li>",
"     <li>",
"      Symmetric polyarthritis, similar and at times indistinguishable from rheumatoid arthritis (RA).",
"     </li>",
"     <li>",
"      Arthritis mutilans, characterized by deforming and destructive arthritis (",
"      <a class=\"graphic graphic_picture graphicRef51683 \" href=\"UTD.htm?19/59/20400\">",
"       picture 10",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58184 \" href=\"UTD.htm?10/36/10831\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Spondyloarthropathy, including both sacroiliitis and spondylitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several HLA types have been associated with psoriatic arthritis, suggesting a genetic predisposition to the development of joint disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23608?source=see_link\">",
"     \"Pathogenesis of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Exacerbating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several drugs are associated with worsening psoriasis or psoriasis-like drug eruptions. The most common offenders are beta blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , and antimalarial drugs. Other drugs that have been reported to worsen psoriasis include angiotensin converting enzyme inhibitors, NSAIDs, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/58\">",
"     58",
"    </a>",
"    ]; however, these drugs have not been definitively associated with exacerbations of psoriasis.",
"   </p>",
"   <p>",
"    Infections, both bacterial and viral, also may be associated with worsening of psoriasis. As noted above, poststreptococcal flares of guttate psoriasis and the onset or worsening of psoriasis in association with HIV infection are well recognized.",
"   </p>",
"   <p>",
"    The prevalence of psoriasis is increased among patients who abuse alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/59\">",
"     59",
"    </a>",
"    ]. Furthermore, in a population-based study, alcoholism was a significant risk factor for mortality among patients with psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/60\">",
"     60",
"    </a>",
"    ]. Alcohol consumption decreases the response to conventional treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/61\">",
"     61",
"    </a>",
"    ], perhaps due to decreased adherence. Furthermore, alcohol consumption and psoriasis itself have been linked to an increased hepatic toxicity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , an important therapeutic option in the treatment of extensive psoriasis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link\">",
"     \"Treatment of psoriasis\"",
"    </a>",
"    ); liver transplantation due to the hepatotoxicity of methotrexate in patients with psoriasis has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;A given patient's course of psoriasis is unpredictable. Psoriasis tends to be a chronic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/63\">",
"     63",
"    </a>",
"    ]. However, there may be marked variability in severity over time, and remissions at some stage are seen in approximately 25 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/64\">",
"     64",
"    </a>",
"    ]. Pruritus may be severe, and arthritis and palmoplantar disease can be disabling. Pustular psoriasis and erythrodermic flares can cause fluid and electrolyte abnormalities that require careful management. Depression and suicidal ideation are reportedly more common in patients with psoriasis than in controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Nevertheless, with the exception of psoriatic arthritis and severe psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/67\">",
"     67",
"    </a>",
"    ], general health and longevity are not affected by psoriasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COMORBIDITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although psoriasis is primarily a disease of the skin, there is an increasing understanding of the prevalence of comorbid conditions in patients with psoriasis.",
"   </p>",
"   <p>",
"    Diseases reported to occur at a higher frequency in patients with psoriasis include cardiovascular disease, malignancy, diabetes, hypertension, metabolic syndrome, inflammatory bowel disease, and serious infections [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27625/abstract/68-77\">",
"     68-77",
"    </a>",
"    ]. The reasons for these associations are not well-understood. Examples of factors that may contribute to the occurrence of comorbid disease in patients with psoriasis include the effects of immune-mediated chronic inflammation, lifestyle factors, and the adverse effects of systemic therapies. The comorbidities of psoriasis are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/63/43001?source=see_link\">",
"     \"Comorbid disease in psoriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the differential diagnosis of psoriasis is broad, a diagnosis of psoriasis can be made by history and physical examination in the vast majority of cases. Rarely, a skin biopsy is performed to rule out other conditions. There are no other laboratory tests that confirm or exclude the diagnosis. An expanded physical examination should be performed with attention to subtle findings in the scalp, umbilicus, intergluteal cleft, and nails when the diagnosis of psoriasis is considered.",
"   </p>",
"   <p>",
"    Seborrheic dermatitis (",
"    <a class=\"graphic graphic_picture graphicRef59104 \" href=\"UTD.htm?27/42/28320\">",
"     picture 11",
"    </a>",
"    ), lichen simplex chronicus (",
"    <a class=\"graphic graphic_picture graphicRef69453 \" href=\"UTD.htm?19/11/19634\">",
"     picture 12",
"    </a>",
"    ), and atopic dermatitis (eczema) (",
"    <a class=\"graphic graphic_picture graphicRef64525 graphicRef55375 \" href=\"UTD.htm?31/48/32520\">",
"     picture 13A-B",
"    </a>",
"    ) may also present with thick demarcated plaques. Features that are suggestive of the diagnosis of psoriasis include a positive family history, no or mild pruritus, and localization of lesions to the elbows, knees, and lower back. Intergluteal erythema, discrete rather than diffuse scalp involvement, and occurrence at sites of trauma (Koebner phenomenon) are also characteristic of psoriasis. In patients who present with erythroderma, the possibility of cutaneous T cell lymphoma also should be considered.",
"   </p>",
"   <p>",
"    When biopsy is necessary (eg, when the clinical examination is insufficient to make the diagnosis), a 4 mm punch biopsy from involved skin is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=see_link&amp;anchor=H12#H12\">",
"     \"Skin biopsy techniques\", section on 'Punch biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Classic histologic findings include epidermal hyperplasia that is regular or uniform in degree, parakeratosis (retention of nuclei in the stratum corneum), neutrophils in the stratum corneum and epidermis, a thinned or absent granular cell layer of the epidermis, and thinning of the suprapapillary dermal plates. Microabscesses with neutrophils may be seen.",
"   </p>",
"   <p>",
"    Early lesions differ from established plaques and may only possess superficial perivascular lymphocytic infiltrates and dilated tortuous capillaries. Additionally, atypical cases and partially treated cases of psoriasis can have histologic findings that are suggestive but not diagnostic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/9/3218?source=see_link\">",
"       \"Patient information: Psoriasis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/11/3252?source=see_link\">",
"       \"Patient information: Psoriasis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/36/36419?source=see_link\">",
"       \"Patient information: Psoriatic arthritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriasis is a common chronic skin disorder typically characterized by erythematous papules and plaques with a silver scale, although other presentations occur.",
"   </p>",
"   <p>",
"    Treatment of psoriasis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link\">",
"     \"Treatment of psoriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Worldwide psoriasis prevalence rates range from 0.6 percent to 4.8 percent. Psoriasis affects men and women equally. Although psoriasis can begin at any age, there seem to be two peaks in onset: one between ages 20 and 30 and another between 50 and 60. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psoriasis appears to be a complex immune-mediated disease in which T-lymphocytes and dendritic cells play a central role. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/45/729?source=see_link\">",
"       \"Pathophysiology of psoriasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Smoking, obesity, and alcohol consumption have been associated with psoriasis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the severity of psoriasis, however it is uncertain whether the association is causal. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Exacerbating factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are a number of forms of psoriasis. Typical plaque psoriasis can usually be recognized with ease, but atypical or nonclassic forms are more difficult to identify. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psoriasis may be associated with multiple comorbidities, including the metabolic syndrome, cardiovascular disease, inflammatory bowel disease, and malignancy. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Comorbidities'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/63/43001?source=see_link\">",
"       \"Comorbid disease in psoriasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A diagnosis of psoriasis can be made by history and physical examination in the vast majority of cases. Rarely, a skin biopsy is needed to rule out other conditions. The differential diagnosis includes seborrheic dermatitis, atopic dermatitis, and lichen simplex chronicus. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/1\">",
"      Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/2\">",
"      Gelfand JM, Stern RS, Nijsten T, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 2005; 52:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/3\">",
"      Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005; 141:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/4\">",
"      Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica 1974; 148:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/5\">",
"      Icen M, Crowson CS, McEvoy MT, et al. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol 2009; 60:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/6\">",
"      Tollefson MM, Crowson CS, McEvoy MT, Maradit Kremers H. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol 2010; 62:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/7\">",
"      Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/8\">",
"      Fortes C, Mastroeni S, Leffondr&eacute; K, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 2005; 141:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/9\">",
"      Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/10\">",
"      Huerta C, Rivero E, Rodr&iacute;guez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007; 143:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/11\">",
"      Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med 2007; 120:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/12\">",
"      Eriksson MO, Hagforsen E, Lundin IP, Micha&euml;lsson G. Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol 1998; 138:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/13\">",
"      Micha&euml;lsson G, Gustafsson K, Hagforsen E. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol 2006; 54:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/14\">",
"      Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/15\">",
"      McGowan JW, Pearce DJ, Chen J, et al. The skinny on psoriasis and obesity. Arch Dermatol 2005; 141:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/16\">",
"      Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007; 167:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/17\">",
"      Bremmer S, Van Voorhees AS, Hsu S, et al. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 63:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/18\">",
"      Koebnick C, Black MH, Smith N, et al. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr 2011; 159:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/19\">",
"      Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/20\">",
"      Higgins E. Alcohol, smoking and psoriasis. Clin Exp Dermatol 2000; 25:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/21\">",
"      Qureshi AA, Dominguez PL, Choi HK, et al. Alcohol intake and risk of incident psoriasis in US women: a prospective study. Arch Dermatol 2010; 146:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/22\">",
"      Orgaz-Molina J, Buend&iacute;a-Eisman A, Arrabal-Polo MA, et al. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: a case-control study. J Am Acad Dermatol 2012; 67:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/23\">",
"      Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/24\">",
"      Eyerich S, Onken AT, Weidinger S, et al. Mutual antagonism of T cells causing psoriasis and atopic eczema. N Engl J Med 2011; 365:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/25\">",
"      Gladman DD, Anhorn KA, Schachter RK, Mervart H. HLA antigens in psoriatic arthritis. J Rheumatol 1986; 13:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/26\">",
"      Eastmond CJ. Psoriatic arthritis. Genetics and HLA antigens. Baillieres Clin Rheumatol 1994; 8:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/27\">",
"      Genetic Analysis of Psoriasis Consortium &amp; the Wellcome Trust Case Control Consortium 2, Strange A, Capon F, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010; 42:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/28\">",
"      Ellinghaus E, Ellinghaus D, Stuart PE, et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 2010; 42:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/29\">",
"      H&uuml;ffmeier U, Uebe S, Ekici AB, et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 2010; 42:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/30\">",
"      Stuart PE, Nair RP, Ellinghaus E, et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 2010; 42:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/31\">",
"      Tsoi LC, Spain SL, Knight J, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 2012; 44:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/32\">",
"      Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997; 6:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/33\">",
"      Sagoo GS, Tazi-Ahnini R, Barker JW, et al. Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in Caucasian and Chinese Hans population. J Invest Dermatol 2004; 122:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/34\">",
"      Mallon E, Bunce M, Wojnarowska F, Welsh K. HLA-CW*0602 is a susceptibility factor in type I psoriasis, and evidence Ala-73 is increased in male type I psoriatics. J Invest Dermatol 1997; 109:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/35\">",
"      Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006; 78:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/36\">",
"      Alenius GM, Jidell E, Nordmark L, Rantap&auml;&auml; Dahlqvist S. Disease manifestations and HLA antigens in psoriatic arthritis in northern Sweden. Clin Rheumatol 2002; 21:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/37\">",
"      Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/38\">",
"      Garcia VE, Chang M, Brandon R, et al. Detailed genetic characterization of the interleukin-23 receptor in psoriasis. Genes Immun 2008; 9:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/39\">",
"      Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009; 41:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/40\">",
"      Hollox EJ, Huffmeier U, Zeeuwen PL, et al. Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 2008; 40:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/41\">",
"      Zhang XJ, Huang W, Yang S, et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet 2009; 41:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/42\">",
"      de Cid R, Riveira-Munoz E, Zeeuwen PL, et al. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 2009; 41:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/43\">",
"      Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/44\">",
"      Pearce DJ, Lucas J, Wood B, et al. Death from psoriasis: representative US data. J Dermatolog Treat 2006; 17:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/45\">",
"      Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992; 128:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/46\">",
"      Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/47\">",
"      Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/48\">",
"      Grover C, Reddy BS, Uma Chaturvedi K. Diagnosis of nail psoriasis: importance of biopsy and histopathology. Br J Dermatol 2005; 153:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/49\">",
"      Viguier M, Allez M, Zagdanski AM, et al. High frequency of cholestasis in generalized pustular psoriasis: Evidence for neutrophilic involvement of the biliary tract. Hepatology 2004; 40:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/50\">",
"      Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol 1989; 21:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/51\">",
"      Rehal B, Modjtahedi BS, Morse LS, et al. Ocular psoriasis. J Am Acad Dermatol 2011; 65:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/52\">",
"      Reveille JD, Conant MA, Duvic M. Human immunodeficiency virus-associated psoriasis, psoriatic arthritis, and Reiter's syndrome: a disease continuum? Arthritis Rheum 1990; 33:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/53\">",
"      Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005; 53:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/54\">",
"      Reich K, Kr&uuml;ger K, M&ouml;ssner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 2009; 160:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/55\">",
"      Radtke MA, Reich K, Blome C, et al. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 2009; 23:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/56\">",
"      Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 2009; 61:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/57\">",
"      Garg A, Gladman D. Recognizing psoriatic arthritis in the dermatology clinic. J Am Acad Dermatol 2010; 63:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/58\">",
"      Gupta AK, Sibbald RG, Knowles SR, et al. Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis. J Am Acad Dermatol 1997; 36:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/59\">",
"      Higgins EM, du Vivier AW. Cutaneous disease and alcohol misuse. Br Med Bull 1994; 50:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/60\">",
"      Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999; 135:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/61\">",
"      Gupta MA, Schork NJ, Gupta AK, Ellis CN. Alcohol intake and treatment responsiveness of psoriasis: a prospective study. J Am Acad Dermatol 1993; 28:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/62\">",
"      Gilbert SC, Klintmalm G, Menter A, Silverman A. Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis. A word of caution in light of the expanding use of this 'steroid-sparing' agent. Arch Intern Med 1990; 150:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/63\">",
"      Nijsten T, Looman CW, Stern RS. Clinical severity of psoriasis in last 20 years of PUVA study. Arch Dermatol 2007; 143:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/64\">",
"      Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol 1996; 135:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/65\">",
"      Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/66\">",
"      Fried RG, Friedman S, Paradis C, et al. Trivial or terrible? The psychosocial impact of psoriasis. Int J Dermatol 1995; 34:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/67\">",
"      Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/68\">",
"      Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/69\">",
"      Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/70\">",
"      Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/71\">",
"      Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005; 129:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/72\">",
"      Pearce DJ, Morrison AE, Higgins KB, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 2005; 16:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/73\">",
"      Makredes M, Robinson D Jr, Bala M, Kimball AB. The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. J Am Acad Dermatol 2009; 61:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/74\">",
"      Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J Invest Dermatol 2009; 129:2604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/75\">",
"      Patel RV, Shelling ML, Prodanovich S, et al. Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature. J Gen Intern Med 2011; 26:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/76\">",
"      Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009; 145:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27625/abstract/77\">",
"      Wakkee M, de Vries E, van den Haak P, Nijsten T. Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. J Am Acad Dermatol 2011; 65:1135.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5664 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-197.136.42.3-BE723D6DBA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_62_27625=[""].join("\n");
var outline_f26_62_27625=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27414545\">",
"      Generalized pustular psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Plaque psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Guttate psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Inverse psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nail psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pustular psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Erythrodermic psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2637210\">",
"      Ocular findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Psoriasis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Exacerbating factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COMORBIDITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5664\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5664|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/36/10831\" title=\"diagnostic image 1\">",
"      Mutilans in psoriasis x ray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5664|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/55/40831\" title=\"picture 1\">",
"      Plaque type psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/9/24725\" title=\"picture 2A\">",
"      Guttate psoriasis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/28/42433\" title=\"picture 2B\">",
"      Guttate psoriasis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/11/42173\" title=\"picture 3A\">",
"      Inverse psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/19/3381\" title=\"picture 3B\">",
"      Inverse psoriasis groin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/48/31492\" title=\"picture 3C\">",
"      Inverse psoriasis chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/54/3937\" title=\"picture 3D\">",
"      Inverse psoriasis gluteal 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/37/41558\" title=\"picture 3E\">",
"      Inverse psoriasis gluteal 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/7/15474\" title=\"picture 4\">",
"      Nail psoriasis pits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/51/33585\" title=\"picture 5\">",
"      Nail psoriasis oil drop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/29/29138\" title=\"picture 6\">",
"      Nail psoriasis hyperkeratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/8/13454\" title=\"picture 7\">",
"      Pustular psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/0/27654\" title=\"picture 8\">",
"      Erythrodermic psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/39/15999\" title=\"picture 9\">",
"      DIP joints psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/59/20400\" title=\"picture 10\">",
"      Arthritis mutilans in psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/42/28320\" title=\"picture 11\">",
"      Seborrheic dermatitis face 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/11/19634\" title=\"picture 12\">",
"      Lichen simplex chronicus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/31/24051\" title=\"picture 13A\">",
"      Adult atopic dermatitis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/10/42147\" title=\"picture 13B\">",
"      Adult atopic dermatitis 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5664|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/37/15963\" title=\"table 1\">",
"      Fitzpatrick skin phototypes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=related_link\">",
"      Clinical manifestations and diagnosis of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/63/43001?source=related_link\">",
"      Comorbid disease in psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=related_link\">",
"      Neutrophilic dermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23608?source=related_link\">",
"      Pathogenesis of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=related_link\">",
"      Pathogenesis of spondyloarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/45/729?source=related_link\">",
"      Pathophysiology of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/11/3252?source=related_link\">",
"      Patient information: Psoriasis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/9/3218?source=related_link\">",
"      Patient information: Psoriasis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/36/36419?source=related_link\">",
"      Patient information: Psoriatic arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=related_link\">",
"      Treatment of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40234?source=related_link\">",
"      Treatment of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31193?source=related_link\">",
"      Vitamin D and extraskeletal health",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_62_27626="Treatment of hypertension in children and adolescents";
var content_f26_62_27626=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hypertension in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/62/27626/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/62/27626/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/62/27626/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/62/27626/contributors\">",
"     F Bruder Stapleton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/62/27626/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/62/27626/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/62/27626/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has become clear that hypertension (HTN) begins in childhood and adolescence and that it contributes to the early development of cardiovascular disease (CVD). In hypertensive adults, multiple randomized trials have shown that reduction of blood pressure (BP) by antihypertensive therapy reduces cardiovascular morbidity and mortality. Based upon these observations, identifying children with HTN and successfully treating their HTN should have an important impact on long-term outcomes of CVD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=see_link\">",
"     \"Hypertension: Who should be treated?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to the treatment of HTN in children and adolescents will be reviewed here. The epidemiology, etiology, diagnosis, and evaluation of HTN are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42105?source=see_link\">",
"     \"Epidemiology, risk factors, and etiology of hypertension in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2729?source=see_link\">",
"     \"Evaluation of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of hypertensive emergencies and urgencies in children is also presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=see_link\">",
"     \"Management of hypertensive emergencies and urgencies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children in the United States, the following definitions based upon the 2004 National High Blood Pressure Education Program Working Group (NHBPEP) are used to classify blood pressure (BP) measurements in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/1\">",
"     1",
"    </a>",
"    ]. BP percentiles are based upon gender, age, and height derived from normative data (",
"    <a class=\"graphic graphic_table graphicRef63856 \" href=\"UTD.htm?7/45/7894\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52646 \" href=\"UTD.htm?7/46/7910\">",
"     table 2",
"    </a>",
"    ). The systolic and diastolic BPs are of equal importance; if there is a disparity between the two, the higher value determines the BP category. The age- and height-specific blood pressure percentiles may be determined using calculators for boys (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or for girls (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal BP &ndash; Both systolic and diastolic BP &lt;90",
"      <sup>",
"       th",
"      </sup>",
"      percentile.",
"     </li>",
"     <li>",
"      Prehypertension &ndash; Systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;90",
"      <sup>",
"       th",
"      </sup>",
"      percentile but &lt;95",
"      <sup>",
"       th",
"      </sup>",
"      percentile",
"      <strong>",
"       or",
"      </strong>",
"      if BP exceeds",
"      <span class=\"nowrap\">",
"       120/80",
"      </span>",
"      mmHg (even if &lt;90",
"      <sup>",
"       th",
"      </sup>",
"      percentile for age, gender, and height).",
"     </li>",
"     <li>",
"      Hypertension (HTN) &ndash; HTN is defined as either systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;95",
"      <sup>",
"       th",
"      </sup>",
"      percentile measured upon three or more separate occasions. The degree of HTN is further delineated by the two following stages.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Stage 1 HTN",
"      </strong>",
"      &ndash; Systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP between the 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile and 5 mmHg above the 99",
"      <sup>",
"       th",
"      </sup>",
"      percentile.",
"     </li>",
"     <li>",
"      <strong>",
"       Stage 2 HTN",
"      </strong>",
"      &ndash; Systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;99",
"      <sup>",
"       th",
"      </sup>",
"      percentile plus 5 mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more complete discussion on the classification of BP, and the definition and diagnosis of HTN in children and adolescents is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link&amp;anchor=H2#H2\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Definition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Childhood HTN is also divided into two categories depending upon whether or not an underlying cause can be identified.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary HTN &ndash; No identifiable cause is found.",
"     </li>",
"     <li>",
"      Secondary HTN &ndash; An underlying cause is identified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RATIONALE FOR INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is no direct evidence that initiating therapy to lower blood pressure (BP) in children and adolescents with persistent hypertension (HTN) lowers the risk of subsequent cardiovascular disease (CVD) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/2\">",
"     2",
"    </a>",
"    ], there are indirect data that HTN in childhood and adolescence contributes to premature atherosclerosis and the early development of cardiovascular disease (CVD), as demonstrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HTN is a well-established risk factor for CVD in adults. Children and adolescents who are hypertensive or have prehypertension are more likely to be hypertensive as adults [",
"      <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link&amp;anchor=H10#H10\">",
"       \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Tracking'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HTN is a risk factor for accelerated atherosclerosis in children and young adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link&amp;anchor=H6#H6\">",
"       \"Risk factors and development of atherosclerosis in childhood\", section on 'Hypertension'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link&amp;anchor=H2#H2\">",
"       \"Risk factors and development of atherosclerosis in childhood\", section on 'Atherosclerotic changes in childhood'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Noninvasive methods of assessment of vascular changes related to atherosclerosis demonstrate an association of higher BP with predictors of CVD including arterial stiffness measured by pulse wave velocity [",
"      <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/3\">",
"       3",
"      </a>",
"      ], arterial calcification [",
"      <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/4,5\">",
"       4,5",
"      </a>",
"      ], and carotid intimal medial thickness evaluated by computed tomography or echocardiography [",
"      <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/5-7\">",
"       5-7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among children and adolescents with borderline or established primary HTN, left ventricular hypertrophy is present in approximately 40 to 45 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. In adults, HTN has been associated with increased left ventricular mass, which is a known risk factor for CVD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/10-12\">",
"       10-12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In hypertensive adults, multiple randomized trials have shown that reduction of BP by antihypertensive therapy reduces cardiovascular morbidity and mortality. The magnitude of the benefit increases with the severity of the HTN. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=see_link\">",
"       \"Hypertension: Who should be treated?\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations suggest lowering the BP in hypertensive children would reduce the risk of accelerated atherosclerosis and subsequently premature CVD.",
"   </p>",
"   <p>",
"    Treatment for HTN includes both nonpharmacologic and pharmacologic interventions. Management decisions are dependent upon the severity of HTN, the underlying cause, and the presence of other CVD risk factors. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Management approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic therapy is recommended by the 2004 National High Blood Pressure Education Program Working Group (NHBPEP) guidelines for children with hypertension (HTN) (defined as blood pressure [BP] &gt;95",
"    <sup>",
"     th",
"    </sup>",
"    percentile) or prehypertension (defined as BP &gt;90",
"    <sup>",
"     th",
"    </sup>",
"    to the 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile",
"    <strong>",
"     or",
"    </strong>",
"    if BP exceeds",
"    <span class=\"nowrap\">",
"     120/80",
"    </span>",
"    mmHg) (",
"    <a class=\"graphic graphic_table graphicRef63856 \" href=\"UTD.htm?7/45/7894\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52646 \" href=\"UTD.htm?7/46/7910\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. The age- and height-specific blood pressure percentiles may be determined using calculators for boys (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or for girls (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In our practice, the following nonpharmacologic measures, which are consistent with the NHBPEP therapeutic lifestyle changes, are used to treat hypertensive and prehypertensive children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight reduction for obesity-related HTN.",
"     </li>",
"     <li>",
"      Regular exercise and restriction of sedentary activity.",
"     </li>",
"     <li>",
"      Dietary modification including salt restriction.",
"     </li>",
"     <li>",
"      Nonpharmacologic measures to reduce other cardiovascular disease (CVD) risk factors, such as smoking and dyslipidemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children and adolescents with prehypertension who are treated with nonpharmacologic interventions should have their BP monitored every four to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/14\">",
"     14",
"    </a>",
"    ]. Those with HTN should be monitored more often depending upon the severity of their HTN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Weight reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BP lowering effect of weight reduction in obese hypertensive adult patients has been well documented, with systolic and diastolic blood pressures falling by approximately 1 mmHg for each 1 kg of weight loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34630?source=see_link\">",
"     \"Obesity and weight reduction in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the data in children are not as robust, several studies have reported results of lower BP values with weight reduction in hypertensive children similar to those seen in adult studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. In the only randomized trial, 72 overweight adolescents were assigned to regimens of diet plus exercise, diet alone, and no intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/16\">",
"     16",
"    </a>",
"    ]. At the end of 20 weeks, there was a similar mean weight loss in the two intervention groups of 2.5 kg but a mean weight gain of 4 kg in the control group. The changes in systolic pressure in the three groups were -16, -10, and +4 mmHg, respectively. Weight loss was associated with an increase in serum HDL-cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/16\">",
"     16",
"    </a>",
"    ], reductions in serum triglycerides and body fat [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/16\">",
"     16",
"    </a>",
"    ], and a decrease in BP sensitivity to sodium intake [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dietary counseling with a nutritionist can be useful in providing customized recommendations to decrease daily caloric intake. Dietary modification should be coupled with a decrease in time spent on sedentary activities and initiation of a regular exercise regimen. In some cases, referral to pediatric obesity centers for appropriate dietary, pharmacologic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical therapy may be warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=see_link\">",
"     \"Clinical evaluation of the obese child and adolescent\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise lowers BP in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/16,20-25\">",
"     16,20-25",
"    </a>",
"    ]. A meta-analysis of 12 randomized trials with 1266 children and adolescents found that short-term physical activity led to a small but not significant reduction of 1 percent in systolic BP and 3 percent in diastolic BP [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a subsequent study of 1170 children and adolescents (age range 8 to 17 years), there was an inverse relationship between the quantity and vigor of physical activity (measured by accelerometers) and systolic and diastolic BP [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/26\">",
"     26",
"    </a>",
"    ]. Participants were less likely to have HTN (defined as BP &ge;90",
"    <sup>",
"     th",
"    </sup>",
"    percentile) if they were engaged in moderate or vigorous physical activity compared with less active subjects (OR 0.5, 95% CI 0.28-0.64, and OR 0.38, 95% CI 0.17-0.52, respectively).",
"   </p>",
"   <p>",
"    Sustained regular physical activity appears to be more effective in lowering BP. This was illustrated in a trial of 137 children, approximately one-half hypertensive (&ge;95",
"    <sup>",
"     th",
"    </sup>",
"    percentile) and one-half normotensive, who were randomly assigned to three extra weekly school physical education sessions or no added exercise for eight months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/20\">",
"     20",
"    </a>",
"    ]. The extra exercise was associated with improved physical fitness and with significant reductions in systolic and diastolic BP in both the hypertensive (4.9 and 3.8 mmHg, respectively) and normotensive children (6.5 and 4.1 mmHg, respectively).",
"   </p>",
"   <p>",
"    As cited above, the antihypertensive effect of physical activity combined with weight loss is greater than that with weight loss or exercise alone. However, the combination of weight loss and physical training may not improve the adverse effects of obesity on left ventricular function or size in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aerobic exercise prescriptions should define the type, frequency, intensity, and duration of activity. Aerobic exercise involves low resistance movements usually over a period of greater than 10 minutes. Activities include walking, running, swimming, and bike riding. The optimal amount and intensity of exercise in children are uncertain. The following recommendations have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American College of Sports Medicine recommends 20 to 60 minutes of aerobic exercise three to four times a week, including warm-up and cool-down periods that involve stretching or walking [",
"      <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/28\">",
"       28",
"      </a>",
"      ]. Exercise intensity should reach a heart rate of 60 to 85 percent of the patient's age-related maximum heart rate. The average maximum heart rate in children and adolescents is considered to be 200",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      with a wide range of individual values.",
"     </li>",
"     <li>",
"      The NHBPEP recommends regular moderate aerobic physical activity of 30 to 60 minutes on most days and limitation of sedentary activities to less than two hours per day [",
"      <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to the effects of regular aerobic exercise, strength-training isometric exercise, which involves high resistance, low repetition movements over short periods of time (one to three minutes) does not appear to lower the BP [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/29\">",
"     29",
"    </a>",
"    ]. Furthermore, these activities (eg, weight lifting) can acutely raise both the systolic and diastolic BP [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/30\">",
"     30",
"    </a>",
"    ]. Isometric exercise should be discouraged until the BP is well controlled.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Sports participation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive long-term data concerning the safety of participation in athletics by children with borderline or mild hypertension (stage 1 HTN) are not available. It is generally believed that these children should be allowed to participate in dynamic aerobic exercise in the absence of end-organ damage (eg, echocardiographic evidence of left ventricular hypertrophy). Patients who become symptomatic should be reevaluated. Because of its possible hypertensive response, weight lifting should be avoided in children with hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Competitive sports participation should be restricted in the presence of uncontrolled stage 2 HTN [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/1\">",
"     1",
"    </a>",
"    ]. Children with stage 2 HTN, once treated with pharmacologic therapy and documented to be normotensive, can participate in aerobic activity with ongoing monitoring. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Pharmacologic therapy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/13/36058?source=see_link&amp;anchor=H3#H3\">",
"     \"The preparticipation sports examination in children and adolescents\", section on 'Conditions that limit participation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data on the effect of dietary changes upon BP in children. However, it is generally accepted based upon adult trials that a reduction in salt intake and an increase intake of fresh fruits and vegetables and low-fat dairy products (eg, the Dietary Approaches to Stop Hypertension [DASH] diet [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/31\">",
"     31",
"    </a>",
"    ]) have beneficial effects in children and adolescents with HTN [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Salt restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased salt intake (both sodium and chloride) is associated with higher blood pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/32\">",
"     32",
"    </a>",
"    ]. Primary hypertension is seen primarily in societies in which salt intake is above 100",
"    <span class=\"nowrap\">",
"     mEq/day",
"    </span>",
"    (2.3 g sodium); in contrast, hypertension is a rare disorder in societies in which salt intake is less than 50",
"    <span class=\"nowrap\">",
"     mEq/day",
"    </span>",
"    (1.2 g sodium) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/33\">",
"     33",
"    </a>",
"    ]. Salt sensitivity is more marked in African-Americans and patients with established hypertension or renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/17,34\">",
"     17,34",
"    </a>",
"    ]. Among children with primary hypertension, increased salt intake may promote the development of left ventricular hypertrophy, independent of any effect on BP [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=see_link\">",
"     \"Salt intake, salt restriction, and essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of salt intake on BP may begin early in life. This was illustrated in a clinical trial in which 476 newborn infants were randomly assigned to a low-sodium diet (about one-third of normal intake) or a normal-sodium diet for the first six months of life [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/36\">",
"     36",
"    </a>",
"    ]. At the end of the study, the systolic BP was 2.1 mmHg lower in infants who received the low-sodium diet. When 167 children from this cohort were examined 15 years later, systolic and diastolic BP were 3.6 and 2.2 mmHg lower in those originally assigned to a low-sodium intake versus those who received a normal sodium diet [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Well-controlled randomized trials in adults have shown that the overall impact of moderate sodium restriction is a fall in systolic and diastolic BP in hypertensive (4.8 and 2.5 mmHg, respectively) and normotensive (1.9 and 1.1 mmHg, respectively) adults (",
"    <a class=\"graphic graphic_figure graphicRef81634 \" href=\"UTD.htm?17/48/18190\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/38\">",
"     38",
"    </a>",
"    ]. Although not all hypertensive adults are salt-sensitive, the general recommendation is to reduce dietary intake from the usual 150 to 200",
"    <span class=\"nowrap\">",
"     mEq/day",
"    </span>",
"    (approximately 9 to 12 g of salt) to 100",
"    <span class=\"nowrap\">",
"     mEq/day",
"    </span>",
"    (approximately 6 g of salt). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=see_link\">",
"     \"Salt intake, salt restriction, and essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evidence for a benefit from salt restriction in children and adolescents with primary hypertension is less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/1\">",
"     1",
"    </a>",
"    ]. Two short-term trials showed no significant BP lowering from sodium restriction in groups of adolescents who represented the entire range of BP percentiles [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Another short-term trial of obese adolescents found a benefit from marked sodium restriction (30 versus 250",
"    <span class=\"nowrap\">",
"     mmol/day)",
"    </span>",
"    that was no longer present after a weight loss of more than 1 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the limited data in children, the NHBPEP has recommended an aggressive and probably difficult to achieve degree of salt restriction, reducing sodium intake to 1.2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    which corresponds to a salt intake of 3.1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (53",
"    <span class=\"nowrap\">",
"     mEq/day)",
"    </span>",
"    in four to eight year old children, and sodium intake of 1.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    which corresponds to a salt intake of 3.8",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (65",
"    <span class=\"nowrap\">",
"     mEq/day)",
"    </span>",
"    in older children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, we begin dietary salt modification with a no-added-salt diet. This also includes a reduction in or elimination of foods containing large amounts of salt (eg, potato chips, pretzels, processed foods). Parents and care providers are encouraged to read food package labels to determine the sodium content of prepared foods and avoid those with high salt content. In addition, lunches provided by school programs need to be evaluated to ensure avoiding foods with high salt content. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"     \"Patient information: Low sodium diet (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Potassium intake and the DASH diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in hypertensive adults have shown that increasing potassium intake can modestly lower the BP. This effect is attenuated or lost in patients also on a low-sodium diet [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/41\">",
"     41",
"    </a>",
"    ], and benefit has not been confirmed in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13060?source=see_link\">",
"     \"Potassium and hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adults, diets that are rich in fresh vegetables and fruits (eg, the Dietary Approaches to Stop Hypertension [DASH] diet), which are low in fat but relatively rich in potassium, have been shown to decrease BP [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/31,43\">",
"     31,43",
"    </a>",
"    ]. In one study of 57 adolescents with either hypertension or prehypertension, there was a greater reduction of systolic BP (SBP) in patients assigned to the DASH diet versus routine outpatient hospital-based nutrition care (mean SBP change of 10.4 versus1.9 mmHg) three months after nutrition counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/44\">",
"     44",
"    </a>",
"    ]. Although not significant, there was a trend towards lower systolic BP in the patients assigned to the DASH diet six months after nutrition counseling (9.3 versus 4.3 mmHg). At the six-month follow-up, 50 percent of the patients assigned to the DASH diet were normotensive versus 36 percent of those who were assigned routine nutritional care.",
"   </p>",
"   <p>",
"    Based upon this study as well as those in adults, a diet rich in fresh vegetables and fruits, such as the DASH diet, is suggested in patients with HTN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=see_link&amp;anchor=H4#H4\">",
"     \"Diet in the treatment and prevention of hypertension\", section on 'DASH trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Avoidance of excess alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies in adults have shown a clear association between excess alcohol intake and the development of hypertension. Adults who have more than two drinks per day have a 1.5- to twofold increase in the incidence of hypertension compared with nondrinkers. This effect is dose-related and is most prominent when intake exceeds five drinks per day. The applicability of these findings to children has not been well studied. Nevertheless, excess alcohol intake should be avoided to improve weight loss, BP control, and other health concerns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=see_link\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other CVD risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking should be avoided by hypertensive children and adolescents because it increases the risk of CVD as well as lung cancer. In addition, smoking by family members should be avoided to prevent second-hand smoke exposure, which has been associated with premature atherosclerosis in exposed children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3395?source=see_link\">",
"     \"Smoking and hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=see_link&amp;anchor=H19#H19\">",
"     \"Secondhand smoke exposure: Effects in children\", section on 'Coronary heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dietary measures should be initiated in children with dyslipidemia, which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23320?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the management of the child at risk for atherosclerosis\", section on 'Dyslipidemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although antihypertensive drug therapy in children has the potential to produce side effects and has not been proven to improve long-term cardiovascular outcome, there is indirect supporting evidence that lowering elevated childhood blood pressure (BP) reduces the risk of premature cardiovascular disease (CVD). These data include demonstration of an association between higher BP in children and predictors of CVD (eg, increased arterial stiffness and calcification, and carotid intimal medial thickness), and that hypertensive children are more likely to remain hypertensive as adults, who are at risk for CVD. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Rationale for intervention'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link\">",
"     \"Risk factors and development of atherosclerosis in childhood\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, drug therapy for hypertension (HTN) in children should be limited to those who are most likely to benefit, and a regimen should be chosen to minimize the incidence of side effects and provide the best possible compliance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Whom to treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our practice, we utilize the 2004 National High Blood Pressure Education Program Working Group (NHBPEP) guidelines to initiate pharmacologic therapy in children with one or more of the following conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic HTN (eg, headache, seizures, changes in mental status, focal neurologic complaints, visual disturbances, and cardiovascular complaints indicative of heart failure, such as chest pain, palpitations, cough, or shortness of breath).",
"     </li>",
"     <li>",
"      Stage 2 HTN defined as BP levels that are 5 mmHg greater than the 99",
"      <sup>",
"       th",
"      </sup>",
"      percentile.",
"     </li>",
"     <li>",
"      Stage 1 HTN (without any evidence of target-organ damage) that persists despite a trial of four to six months of nonpharmacologic therapy.",
"     </li>",
"     <li>",
"      Hypertensive target-organ damage, most often left ventricular hypertrophy (LVH). LVH, defined as left ventricular mass above the 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile, is present in up to 40 to 50 percent of children with primary HTN and is severe (&gt;99",
"      <sup>",
"       th",
"      </sup>",
"      percentile) in as many as 14 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/9\">",
"       9",
"      </a>",
"      ]. Retinal changes are a less common manifestation of target-organ damage in children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21859?source=see_link\">",
"       \"Ocular effects of hypertension\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2729?source=see_link&amp;anchor=H6#H6\">",
"       \"Evaluation of hypertension in children and adolescents\", section on 'Initial evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stage 1 HTN in patients with diabetes mellitus or other risk CVD factors, such as dyslipidemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"       \"Treatment of hypertension in patients with diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23320?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of the management of the child at risk for atherosclerosis\", section on 'Hypertension'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prehypertension in presence of comorbid conditions, such as chronic kidney disease or diabetes mellitus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antihypertensive drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of antihypertensive drugs in children that have been systematically studied has increased due to the 1997 Food and Drug Administration Modernization Act (FDAMA) and the 2002 Best Pharmaceuticals for Children Act. However, this legislation did not affect older commonly used drugs whose patent protection had expired.",
"   </p>",
"   <p>",
"    The 2004 NHBPEP report included dosing recommendations for antihypertensive drugs (",
"    <a class=\"graphic graphic_table graphicRef71466 \" href=\"UTD.htm?13/30/13807\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/1\">",
"     1",
"    </a>",
"    ]. These recommendations were based upon data from industry-sponsored clinical trials and single center observational studies. When data were not available, recommendations were based from collective clinical experience and consensus opinions from experts in the field.",
"   </p>",
"   <p>",
"    The initial choice of antihypertensive agent is discussed in the section on management approach. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Choice of drug'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Thiazide diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an extensive clinical experience confirming the efficacy and safety of thiazide diuretics in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/45\">",
"     45",
"    </a>",
"    ]. In addition to being used as primary therapy, a thiazide diuretic also enhances the effect of many other antihypertensive drugs (eg, ACE inhibitors and beta blockers) when given as combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Optimal efficacy of thiazides, given alone or in combination with other drugs, requires concurrent salt restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=see_link\">",
"     \"Salt intake, salt restriction, and essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of clinical trials in adults with primary hypertension have shown that low-dose thiazide therapy (eg, 12.5 to a maximum of 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/29/42454?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/46/35557?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    ) is effective in lowering BP (",
"    <a class=\"graphic graphic_figure graphicRef61248 \" href=\"UTD.htm?18/24/18829\">",
"     figure 2",
"    </a>",
"    ). Despite these observations, many pediatric specialists in hypertension have recommended primary therapy with ACE inhibitors, beta blockers, or calcium channel blockers rather than diuretic therapy because of concerns about the metabolic complications (eg, hypokalemia, glucose intolerance, adverse lipid effects) associated with diuretic therapy and the need for periodic blood chemistry monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15350?source=see_link\">",
"     \"Use of thiazide diuretics in patients with primary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon adult data and recommendation regarding the use of thiazide diuretics as initial therapy in most patients, we suggest that low-dose thiazide diuretics be considered as initial therapy in post-pubertal adolescents with primary HTN because of its established efficacy and low cost. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Primary hypertension'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     ACE inhibitors/ARBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/20/18760?source=see_link\">",
"     captopril",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/18/32040?source=see_link\">",
"     enalapril",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/38/15976?source=see_link\">",
"     lisinopril",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/41/42647?source=see_link\">",
"     fosinopril",
"    </a>",
"    ) are well tolerated and widely used in hypertensive children. They inhibit the production of angiotensin II by blocking the angiotensin-converting enzyme. Captopril was the first available ACE inhibitor used in pediatrics but it has been supplanted by longer acting ACE inhibitors. In children, efficacy and dosing data are available for enalapril, lisinopril,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/5/40023?source=see_link\">",
"     benazepril",
"    </a>",
"    , and fosinopril.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/18/32040?source=see_link\">",
"     Enalapril",
"    </a>",
"    has received Food and Drug Administration (FDA) approval as an antihypertensive drug for children following completion of both a pharmacokinetic and a dose-dependent trial. The former demonstrated similar pharmacokinetics in infants and children when compared to adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/50\">",
"     50",
"    </a>",
"    ], while the latter demonstrated a dose-dependent response with a low incidence of side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/38/15976?source=see_link\">",
"     Lisinopril",
"    </a>",
"    has been shown to be effective and safe based on a randomized placebo-controlled study of 115 children between the ages of 6 and 16 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/52\">",
"     52",
"    </a>",
"    ]. In another study, pharmacokinetic data were obtained in 46 children between the ages of 6 months and 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/53\">",
"     53",
"    </a>",
"    ]. Based upon a dose that ranged between 0.1 and 0.2",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    pharmacokinetics of lisinopril in children were similar to those reported in adults with a peak serum concentration between five and six hours after administration. There were no drug-related adverse effects. Lisinopril is FDA approved for children between 6 and 16 years of age.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/41/42647?source=see_link\">",
"     Fosinopril",
"    </a>",
"    has been shown to reduce blood pressure in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/54\">",
"     54",
"    </a>",
"    ], although dosing recommendations are limited to children greater than 50 kg. There appears to be differences in dose response based upon ethnicity. Black children appear to require a higher dose per body weight to achieve similar BP reduction compared with non-black children (ie, white, Asian, and Latino children). This was illustrated in a clinical trial of 250 children between 6 and 16 years of age who were randomly selected to receive varying doses of fosinopril [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/55\">",
"     55",
"    </a>",
"    ]. Non-black children had a mean decrease of 12 mmHg in their systolic BP whether a low or high dose of fosinopril was used. In contrast, black children who received a low dose of fosinopril had a lower decrease in systolic BP of a mean of 5 mmHg decrease, while those who received a high dose had a mean reduction of 13 mmHg in SBP, similar to the response in non-black children.",
"   </p>",
"   <p>",
"    Studies in adults suggest that the antihypertensive effect of ACE inhibitors is increased by concurrent salt restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/56\">",
"     56",
"    </a>",
"    ]. Salt restriction increases renin release, making the BP more angiotensin II-dependent and therefore more responsive to therapy with an ACE inhibitor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=see_link\">",
"     \"Renin-angiotensin system inhibition in the treatment of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Angiotensin-receptor blockers (ARBs) block the binding of angiotensin II to the AT1 receptor. ARBs used in children include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/5/26710?source=see_link\">",
"     irbesartan",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/19/40247?source=see_link\">",
"     losartan",
"    </a>",
"    , which have been FDA approved based upon clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/1,57,58\">",
"     1,57,58",
"    </a>",
"    ]. However, in a larger efficacy study, irbesartan failed to show a beneficial effect in hypertensive children between 6 and 16 years of age. This study has not been published, but FDA review of the data are available [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. As a result, irbesartan is not recommended as a pediatric antihypertensive agent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/59\">",
"     59",
"    </a>",
"    ]. A review of the literature reported that ARBs were effective and safe in lowering BP and proteinuria in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who have bilateral renovascular hypertension or are volume depleted, ACE inhibitors or ARBs may reduce the glomerular filtration rate, as manifested by a rise in the plasma creatinine concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/62\">",
"     62",
"    </a>",
"    ]. In these patients with volume depletion or impaired renal function, these medications should be used with caution or another class of antihypertensive agents should be chosen as significant adverse effects have been reported, especially in preschool children who are more vulnerable to hypovolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/63\">",
"     63",
"    </a>",
"    ]. ACE inhibitors and ARBs are",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in pregnancy and should be avoided in sexually active girls (unless they are on birth control measures) because of known adverse effects on the fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers were among the first and most widely used antihypertensive drugs in children. Most of the original studies were performed with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/62/36840?source=see_link\">",
"     propranolol",
"    </a>",
"    , which has been largely replaced by better tolerated, longer acting, and more selective drugs such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/58/34726?source=see_link\">",
"     atenolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/11/15544?source=see_link\">",
"     metoprolol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    . These agents are available in combination with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/29/42454?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    .",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=see_link\">",
"     Labetalol",
"    </a>",
"    is another beta blocker agent, which also has alpha-blocking activity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/46,64,65\">",
"     46,64,65",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/48/5895?source=see_link\">",
"     Esmolol",
"    </a>",
"    is an intravenous beta blocker agent, primarily used to treat postoperative or intraoperative tachycardia and HTN [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of an extended-release (ER) form of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/11/15544?source=see_link\">",
"     metoprolol",
"    </a>",
"    , a cardioselective beta blocker, was demonstrated in a randomized trial of 140 hypertensive children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/66\">",
"     66",
"    </a>",
"    ]. Systolic blood pressure was significantly reduced in patients who received 1 or 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    doses of ER metoprolol compared with those who received placebo. Diastolic blood pressure was only lowered in patients who received 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    doses. During an open label, separate, 52-week trial of 100 patients, five patients discontinued metoprolol because of adverse effects (fatigue, nightmare, anxiety, dizziness, and asthma). Two patients had a serious adverse events; one patient each with pneumonia and menometrorrhagia.",
"   </p>",
"   <p>",
"    Beta blockers are contraindicated in patients with asthma or heart block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing experience with long-acting calcium channel blockers (such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/2/9256?source=see_link\">",
"     nifedipine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/22/36199?source=see_link\">",
"     amlodipine",
"    </a>",
"    ) demonstrate their efficacy and safety in children with hypertension, particularly primary HTN [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/67-70\">",
"     67-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multi-center, randomized, double blinded study of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/22/36199?source=see_link\">",
"     amlodipine",
"    </a>",
"    that included 268 children between 6 and 16 years of age with stage 1 HTN demonstrated the effectiveness of amlodipine over a short period of time (eight weeks) with a relatively small number of significant side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/69\">",
"     69",
"    </a>",
"    ]. The causes of HTN varied and included primary HTN in 50 percent of the patients. In addition, an observational study of 33 children treated for more than six months demonstrated continued effectiveness of amlodipine without significant side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a randomized, placebo controlled three-week trial of another long-acting calcium channel blocker, extended release",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/48/8966?source=see_link\">",
"     felodipine",
"    </a>",
"    , failed to show a fall in systolic BP greater than placebo at any dose in 133 children with primary HTN [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One problem with these long-acting preparations is the minimum dose formulation that is currently available resulted in a range of mean daily dose from 0.06 to 0.23",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in these studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/67,69\">",
"     67,69",
"    </a>",
"    ]. Thus, smaller children who received larger dose of medication per body weight may be more likely to experience dose-related adverse effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=see_link\">",
"     \"Major side effects and safety of calcium channel blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcium channel blockers are contraindicated in patients with sick sinus syndrome, but may be the desired class of antihypertensive agents in patients with HTN and asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MANAGEMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our management approach is to use nonpharmacologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pharmacologic interventions based upon defined target blood pressure (BP) thresholds and goals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Target blood pressure goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children and adolescents with elevated BP, the desired goal is to lower BP to an optimal level that reduces the risk of premature cardiovascular disease (CVD). However, no data are available to define these pediatric goals because long-term epidemiologic data linking cardiovascular events to childhood BP values are lacking. As a result, target blood pressure goals have been determined by expert opinion and are based upon statistically defined BP classification [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link&amp;anchor=H2#H2\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Definition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2004, the National High Blood Pressure Education Program Working Group (NHBPEP), which was comprised of experts in the field, revised target blood pressure goals for the treatment of hypertension (HTN) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/1\">",
"     1",
"    </a>",
"    ]. In our practice, we use the following NHBPEP goals:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children and adolescents with HTN and no evidence of target-organ damage, comorbid risk factors, or diseases associated with CVD; the targeted goal for BP is less than the 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile based upon age, height, and gender (",
"      <a class=\"graphic graphic_table graphicRef63856 \" href=\"UTD.htm?7/45/7894\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52646 \" href=\"UTD.htm?7/46/7910\">",
"       table 2",
"      </a>",
"      ). The age- and height-specific blood pressure percentiles may be determined using calculators for boys (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) or for girls (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"       calculator 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If there are comorbid CVD risk factors (eg, obesity or dyslipidemia), diseases associated with CVD (eg, diabetes mellitus), or chronic kidney disease, the BP targeted goal is lowered to below the 90",
"      <sup>",
"       th",
"      </sup>",
"      percentile for age, height, and gender. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link\">",
"       \"Risk factors and development of atherosclerosis in childhood\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"       \"Treatment of hypertension in patients with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initiation and aggressiveness of the therapy are generally based upon the severity of HTN, and the presence of target-organ damage, symptoms, or other CVD risk factors. Therapy includes nonpharmacologic and pharmacologic interventions and is focused upon achieving the previously discussed BP target goals.",
"   </p>",
"   <p>",
"    Our management approach is consistent with the following NHBPEP guidelines. The choice of antihypertensive agent is discussed below. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Choice of drug'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children who are prehypertensive (BP &gt;90",
"      <sup>",
"       th",
"      </sup>",
"      percentile and &lt;95",
"      <sup>",
"       th",
"      </sup>",
"      percentile), nonpharmacologic therapy (eg, diet and exercise) is initiated to reduce their BP to below the 90",
"      <sup>",
"       th",
"      </sup>",
"      percentile. If there are comorbid CVD factors or diseases associated with CVD (eg, obesity or diabetes mellitus), evaluation for target-organ damage is suggested. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2729?source=see_link&amp;anchor=H11#H11\">",
"       \"Evaluation of hypertension in children and adolescents\", section on 'Laboratory evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In children with stage 1 primary HTN without evidence of target-organ damage, nonpharmacologic therapy is the initial intervention. If BP target goals are not met within four to six months after initial therapy (ie, BP below the 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile), pharmacologic therapy is suggested. The choice of antihypertensive agents is discussed below. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Choice of drug'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In children with stage 1 HTN who are symptomatic or have evidence of target-organ damage (eg, left ventricular hypertrophy), both nonpharmacologic and pharmacologic therapy are started.",
"     </li>",
"     <li>",
"      In children with stage 2 HTN, we recommend treatment with both nonpharmacologic and pharmacologic therapy. Patients with stage 2 HTN and neurologic symptoms including headache, mental status changes, and neurologic findings should be emergently evaluated and treated.",
"     </li>",
"     <li>",
"      In children with secondary HTN, therapy should be directed to correcting the underlying cause, if possible. If the underlying cause cannot be corrected so that HTN is abolished, pharmacologic therapy and nonpharmacologic therapy are initiated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42105?source=see_link&amp;anchor=H15#H15\">",
"       \"Epidemiology, risk factors, and etiology of hypertension in children and adolescents\", section on 'Secondary hypertension'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Choice of drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, long-term clinical outcome trials have evaluated the comparable effectiveness of specific antihypertensive drugs directly. However, in children with hypertension there are no similar comparative data on which to base a recommendation for initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/59\">",
"     59",
"    </a>",
"    ]. Therefore, the NHBPEP guidelines do not make recommendations on the choice of agent for initial therapy and suggest that the choice is based upon the preference and experience of the responsible clinician. However, adult outcome data have demonstrated that certain classes of antihypertensive drugs may be more appropriate for children with a specific underlying medical conditions, such as primary hypertension, chronic kidney disease, and diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children more likely to have a secondary cause of HTN (eg, prepubertal patients or those with stage 2 HTN), we prefer to use calcium channel blockers during the preliminary investigations because of concerns of undiagnosed bilateral renal artery stenosis or renal artery stenosis in a single kidney.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Primary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, there has not been a consensus on the best initial pharmacologic agent to treat primary HTN. The available classes of drugs include thiazide diuretics, ACE inhibitors, beta blockers, and calcium channel blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/1\">",
"     1",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef71466 \" href=\"UTD.htm?13/30/13807\">",
"     table 3",
"    </a>",
"    ). Thiazide diuretics and beta blockers have a long history of safety and efficacy based on clinical experience. Clinical short term trials have shown that ACE inhibitors and calcium channel blockers are effective, safe, and well tolerated in children, but these two classes of drugs are more expensive.",
"   </p>",
"   <p>",
"    Based upon clinical trials in adults, low-dose thiazide therapy is the recommended initial therapy of choice for most patients with primary HTN. Although similar data in hypertensive children do not exist, it is reasonable to assume that low-dose thiazide diuretic therapy would have similar efficacy in adolescents with primary HTN. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Thiazide diuretics'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15350?source=see_link\">",
"     \"Use of thiazide diuretics in patients with primary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data on the use of combination therapy of thiazide diuretics and other classes of antihypertensive medications (beta blockers, ACE inhibitors, and calcium channel blockers) are limited in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H24#H24\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Combination therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our practice, we use",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/29/42454?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    at a starting dose of 12.5 mg daily as initial therapy in adolescents with primary hypertension without evidence of target-organ damage. The dose is increased to 25 mg daily if the target blood pressure goal is not met after two to three months of therapy. If there is no significant response in four to six months after the start of hydrochlorothiazide, we will either add or change to an ACE inhibitor or calcium change blocker.",
"   </p>",
"   <p>",
"    In adults with primary HTN, there is evidence that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/46/35557?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    , which is 1.5 to 2 times as potent as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/29/42454?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    and has a longer duration of action, is associated with increased cardiovascular benefit when compared with ACE inhibitors and calcium channel blockers. However, there has been no trial directly comparing these two thiazide diuretic agents. Because of its increased potency, chlorthalidone is more likely to cause hypokalemia than the same dose of hydrochlorothiazide, and monitoring serum potassium is primary when using this drug. There are no data on the use of this diuretic agent in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H5#H5\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Chlorthalidone versus hydrochlorothiazide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults with chronic renal disease, prospective randomized trials have shown the benefit of ACE inhibitors and angiotensin-receptor blockers (ARBs) in delaying the progression of renal insufficiency. Studies on the use of ACE inhibitors in children are limited, but are consistent with the adult data. ACE inhibitor therapy appears most beneficial in patients with glomerular disease and proteinuria and should be considered as the initial therapy in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/73\">",
"     73",
"    </a>",
"    ]. Close monitoring for possible increases in creatinine and potassium is needed. A more complete discussion on treatment of HTN in children with chronic kidney disease is discussed separately. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'ACE inhibitors/ARBs'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the management of chronic kidney disease in children\", section on 'Hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few data on the use of ARBs in children with chronic renal failure, but based upon the adult data, these drugs are a reasonable alternative if ACE inhibitors cannot be used because of intolerable side effects (most often cough). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized controlled trials in adults have demonstrated that ACE inhibitors and ARBs delay the progression of diabetic nephropathy and decrease albuminuria in patients with both type 1 and type 2 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More limited studies in children with type 1 diabetic nephropathy suggest a similar benefit with ACE inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/73\">",
"     73",
"    </a>",
"    ]. Thus, ACE inhibitors, or, if not tolerated, ARBs, are the preferred drugs in children with diabetes because of their potential renoprotective properties. Because of the increased risk of premature CVD, therapy is targeted to decrease blood pressure values below the 90",
"    <sup>",
"     th",
"    </sup>",
"    percentile for age, gender, and height for patients with either type 1 or 2 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40410?source=see_link&amp;anchor=H25#H25\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\", section on 'Hypertension'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34249?source=see_link&amp;anchor=H3#H3\">",
"     \"Comorbidities and complications of type 2 diabetes mellitus in children and adolescents\", section on 'Hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HTN in type 2 diabetes is usually related to obesity; thus, weight reduction is an important component of hypertension therapy in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Drug management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of antihypertensive therapy is based upon the following considerations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First-line drug therapy should combine efficacy with minimum side effects. Starting doses should be the lowest known effective dose (",
"      <a class=\"graphic graphic_table graphicRef71466 \" href=\"UTD.htm?13/30/13807\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If the target blood pressure goal is not met, a different class of antihypertensive agent is tried and dose titrated to patient response.",
"     </li>",
"     <li>",
"      If the target blood pressure is still not achieved, a second drug from a different class is added when the initial drug dose reaches the highest recommended level or if the patient begins to experience side effects from the initial drug. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Target blood pressure goals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To improve compliance, long-acting agents should be used whenever possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Continued follow-up is required to monitor the response to therapy and to detect any drug-related adverse effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Discontinuation of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults with well-controlled mild hypertension, studies have demonstrated that between 5 and 55 percent remain normotensive for at least one to two years after discontinuation of treatment, while other patients do well with a decrease in drug dose [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. The wide reported range is dependent upon the characteristics of the population studied. Factors such as white-coat hypertension and use of nonpharmacologic therapies are associated with a greater likelihood of successful treatment withdrawal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18068?source=see_link\">",
"     \"Can therapy be discontinued in well-controlled hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The application of these observations to children is clearly speculative. Gradual discontinuation of therapy is most likely to be effective in children with mild initial hypertension who are well controlled on a single drug and who can be maintained on nonpharmacologic therapy such as weight loss and sodium restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/62/27626/abstract/74\">",
"     74",
"    </a>",
"    ]. This \"step-down\" approach can be tried in those selected patients who fulfill these criteria. These patients will require ongoing nonpharmacologic therapy and BP monitoring after drug therapy is discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/37/30290?source=see_link\">",
"       \"Patient information: High blood pressure in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/28/38337?source=see_link\">",
"       \"Patient information: High blood pressure in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/58/931?source=see_link\">",
"       \"Patient information: High blood pressure treatment in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic decisions are dependent upon the severity of hypertension (HTN), the underlying cause, and the presence of other cardiovascular disease (CVD) risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30228111\">",
"    <span class=\"h2\">",
"     Therapeutic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for childhood HTN includes both nonpharmacologic and pharmacologic interventions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonpharmacologic therapy (ie, lifestyle changes) includes weight reduction for children who are overweight, a regular aerobic exercise regimen, dietary measures (eg, salt restriction), and avoidance of excess alcohol consumption and smoking. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacologic agents used frequently in children that are efficacious and safe include thiazide diuretics, angiotensin converting enzyme (ACE) inhibitors, beta blockers, and calcium channel blockers (",
"      <a class=\"graphic graphic_table graphicRef71466 \" href=\"UTD.htm?13/30/13807\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antihypertensive drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is directed towards achieving the following blood pressure (BP) target goals recommended by the National High Blood Pressure Education Program Working Group (NHBPEP). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Target blood pressure goals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children and adolescents with HTN and with no evidence of target-organ damage or comorbid CVD conditions, the targeted goal for blood pressure (BP) is less than the 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile based upon age, height, and gender (",
"      <a class=\"graphic graphic_table graphicRef63856 \" href=\"UTD.htm?7/45/7894\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52646 \" href=\"UTD.htm?7/46/7910\">",
"       table 2",
"      </a>",
"      ). The age- and height-specific blood pressure percentiles may be determined using calculators for boys (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) or for girls (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"       calculator 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If there are comorbid CVD risk factors (eg, obesity or dyslipidemia), diseases associated with CVD (eg, diabetes mellitus), or chronic kidney disease, the BP targeted goal is lowered to below the 90",
"      <sup>",
"       th",
"      </sup>",
"      percentile for age, height, and gender. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link\">",
"       \"Risk factors and development of atherosclerosis in childhood\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H21\">",
"       'Target blood pressure goals'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30228125\">",
"    <span class=\"h2\">",
"     Management approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2004, NHBPEP defined BP classes based upon BP percentiles derived from normative data (",
"    <a class=\"graphic graphic_table graphicRef63856 \" href=\"UTD.htm?7/45/7894\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52646 \" href=\"UTD.htm?7/46/7910\">",
"     table 2",
"    </a>",
"    ). Our management approach is to initiate nonpharmacologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pharmacologic interventions based upon these blood pressure classes and is consistent with the NHBPEP guidelines. In general, all patients who are treated should initiate lifestyle changes whether or not pharmacologic therapy is used. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H22\">",
"     'Our approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest treating prehypertensive children and adolescents with lifestyle changes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest not initiating pharmacologic therapy in such patients even if lifestyle changes are ineffective (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, prehypertensive patients with comorbid conditions, such as chronic kidney disease, should be treated with both pharmacologic and nonpharmacologic therapy.",
"     </li>",
"     <li>",
"      We suggest treating children and adolescents with asymptomatic stage I HTN and no comorbid conditions with lifestyle changes (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In cases where BP does not come down to the targeted BP goal with lifestyle changes alone, we suggest initiating pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend treating children and adolescents with stage I HTN with other CVD risk conditions (eg, dyslipidemia or diabetes mellitus) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest initiating pharmacologic therapy rather than a trial of lifestyle changes alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend treating children and adolescents with stage I HTN with symptoms or evidence of target-organ damage, or with stage II HTN (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We recommend initiating pharmacologic therapy rather than a trial of lifestyle changes alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In children with secondary HTN, therapy should be directed to correcting the underlying cause, if possible. If the underlying cause cannot be corrected so that HTN is abolished, we suggest treatment with both antihypertensive pharmacologic and lifestyle changes (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42105?source=see_link&amp;anchor=H15#H15\">",
"       \"Epidemiology, risk factors, and etiology of hypertension in children and adolescents\", section on 'Secondary hypertension'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36868653\">",
"    <span class=\"h3\">",
"     Choice of antihypertensive agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no long-term clinical outcome measures to evaluate the comparative effectiveness of specific antihypertensive drugs in children with HTN. Based upon data from adult studies, we suggest that the following underlying medical conditions be treated with a specific class of antihypertensive drugs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In adolescents with primary HTN without target-organ damage, we suggest that low-dose thiazide diuretic therapy be used as the first antihypertensive agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Primary hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with chronic kidney disease, we suggest that ACE inhibitors be used as the initial antihypertensive agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In patients who cannot tolerate ACE inhibitors, angiotensin-receptor blockers (ARBs) are a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Chronic kidney disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with either type 1 or type 2 diabetes mellitus, we suggest that ACE inhibitors be used as the initial antihypertensive agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In patients who cannot tolerate ACE inhibitors, angiotensin-receptor blockers (ARBs) are a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Diabetes mellitus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/1\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/2\">",
"      Thompson M, Dana T, Bougatsos C, et al. Screening for hypertension in children and adolescents to prevent cardiovascular disease. Pediatrics 2013; 131:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/3\">",
"      Li S, Chen W, Srinivasan SR, Berenson GS. Childhood blood pressure as a predictor of arterial stiffness in young adults: the bogalusa heart study. Hypertension 2004; 43:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/4\">",
"      Mahoney LT, Burns TL, Stanford W, et al. Coronary risk factors measured in childhood and young adult life are associated with coronary artery calcification in young adults: the Muscatine Study. J Am Coll Cardiol 1996; 27:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/5\">",
"      Davis PH, Dawson JD, Mahoney LT, Lauer RM. Increased carotid intimal-medial thickness and coronary calcification are related in young and middle-aged adults. The Muscatine study. Circulation 1999; 100:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/6\">",
"      Raitakari OT, Juonala M, Taittonen L, et al. Pulse pressure in youth and carotid intima-media thickness in adulthood: the cardiovascular risk in young Finns study. Stroke 2009; 40:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/7\">",
"      Sorof JM, Alexandrov AV, Cardwell G, Portman RJ. Carotid artery intimal-medial thickness and left ventricular hypertrophy in children with elevated blood pressure. Pediatrics 2003; 111:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/8\">",
"      Daniels SR, Witt SA, Glascock B, et al. Left atrial size in children with hypertension: the influence of obesity, blood pressure, and left ventricular mass. J Pediatr 2002; 141:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/9\">",
"      Daniels SR, Loggie JM, Khoury P, Kimball TR. Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension. Circulation 1998; 97:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/10\">",
"      Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/11\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/12\">",
"      Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002; 288:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/13\">",
"      Williams CL, Hayman LL, Daniels SR, et al. Cardiovascular health in childhood: A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2002; 106:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/14\">",
"      Pappadis SL, Somers MJ. Hypertension in adolescents: a review of diagnosis and management. Curr Opin Pediatr 2003; 15:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/15\">",
"      Sorof J, Daniels S. Obesity hypertension in children: a problem of epidemic proportions. Hypertension 2002; 40:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/16\">",
"      Rocchini AP, Katch V, Anderson J, et al. Blood pressure in obese adolescents: effect of weight loss. Pediatrics 1988; 82:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/17\">",
"      Rocchini AP, Key J, Bondie D, et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med 1989; 321:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/18\">",
"      Wabitsch M, Hauner H, Heinze E, et al. Body-fat distribution and changes in the atherogenic risk-factor profile in obese adolescent girls during weight reduction. Am J Clin Nutr 1994; 60:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/19\">",
"      Holm JC, Gamborg M, Neland M, et al. Longitudinal changes in blood pressure during weight loss and regain of weight in obese boys and girls. J Hypertens 2012; 30:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/20\">",
"      Hansen HS, Froberg K, Hyldebrandt N, Nielsen JR. A controlled study of eight months of physical training and reduction of blood pressure in children: the Odense schoolchild study. BMJ 1991; 303:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/21\">",
"      Rocchini AP, Katch V, Schork A, Kelch RP. Insulin and blood pressure during weight loss in obese adolescents. Hypertension 1987; 10:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/22\">",
"      Kelley GA, Kelley KS, Tran ZV. The effects of exercise on resting blood pressure in children and adolescents: a meta-analysis of randomized controlled trials. Prev Cardiol 2003; 6:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/23\">",
"      Gidding SS, Barton BA, Dorgan JA, et al. Higher self-reported physical activity is associated with lower systolic blood pressure: the Dietary Intervention Study in Childhood (DISC). Pediatrics 2006; 118:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/24\">",
"      Farpour-Lambert NJ, Aggoun Y, Marchand LM, et al. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children. J Am Coll Cardiol 2009; 54:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/25\">",
"      Knowles G, Pallan M, Thomas GN, et al. Physical activity and blood pressure in primary school children: a longitudinal study. Hypertension 2013; 61:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/26\">",
"      Mark AE, Janssen I. Dose-response relation between physical activity and blood pressure in youth. Med Sci Sports Exerc 2008; 40:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/27\">",
"      Mitchell BM, Gutin B, Kapuku G, et al. Left ventricular structure and function in obese adolescents: relations to cardiovascular fitness, percent body fat, and visceral adiposity, and effects of physical training. Pediatrics 2002; 109:E73.",
"     </a>",
"    </li>",
"    <li>",
"     Rowland TW. Aerobic exercise testing protocols. In: Pediatric laboratory exercise testing, Rowland TW (Ed), Human Kinetics, Champaign 1993. p.19.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/29\">",
"      Physical exercise in the management of hypertension: a consensus statement by the World Hypertension League. J Hypertens 1991; 9:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/30\">",
"      Morales MC, Coplan NL, Zabetakis P, Gleim GW. Hypertension: the acute and chronic response to exercise. Am Heart J 1991; 122:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/31\">",
"      Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/32\">",
"      Yang Q, Zhang Z, Kuklina EV, et al. Sodium intake and blood pressure among US children and adolescents. Pediatrics 2012; 130:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/33\">",
"      Elliott P, Stamler J, Nichols R, et al. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. Intersalt Cooperative Research Group. BMJ 1996; 312:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/34\">",
"      Campese VM. Salt sensitivity in hypertension. Renal and cardiovascular implications. Hypertension 1994; 23:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/35\">",
"      Daniels SD, Meyer RA, Loggie JM. Determinants of cardiac involvement in children and adolescents with essential hypertension. Circulation 1990; 82:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/36\">",
"      Hofman A, Hazebroek A, Valkenburg HA. A randomized trial of sodium intake and blood pressure in newborn infants. JAMA 1983; 250:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/37\">",
"      Geleijnse JM, Hofman A, Witteman JC, et al. Long-term effects of neonatal sodium restriction on blood pressure. Hypertension 1997; 29:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/38\">",
"      Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr 1997; 65:643S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/39\">",
"      Cooper R, Van Horn L, Liu K, et al. A randomized trial on the effect of decreased dietary sodium intake on blood pressure in adolescents. J Hypertens 1984; 2:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/40\">",
"      Howe PR, Cobiac L, Smith RM. Lack of effect of short-term changes in sodium intake on blood pressure in adolescent schoolchildren. J Hypertens 1991; 9:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/41\">",
"      Grimm RH Jr, Neaton JD, Elmer PJ, et al. The influence of oral potassium chloride on blood pressure in hypertensive men on a low-sodium diet. N Engl J Med 1990; 322:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/42\">",
"      Sinaiko AR, Gomez-Marin O, Prineas RJ. Effect of low sodium diet or potassium supplementation on adolescent blood pressure. Hypertension 1993; 21:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/43\">",
"      John JH, Ziebland S, Yudkin P, et al. Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: a randomised controlled trial. Lancet 2002; 359:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/44\">",
"      Couch SC, Saelens BE, Levin L, et al. The efficacy of a clinic-based behavioral nutrition intervention emphasizing a DASH-type diet for adolescents with elevated blood pressure. J Pediatr 2008; 152:494.",
"     </a>",
"    </li>",
"    <li>",
"     Feld LG, Waz WR. Treatment of hypertension. In: Pediatric Nephrology, Barratt TM, Avner ED, Harmon WE (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 1999. p.63.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/46\">",
"      Sorof JM, Cargo P, Graepel J, et al. Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatr Nephrol 2002; 17:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/47\">",
"      Berenson GS, Shear CL, Chiang YK, et al. Combined low-dose medication and primary intervention over a 30-month period for sustained high blood pressure in childhood. Am J Med Sci 1990; 299:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/48\">",
"      Ram CV, Garrett BN, Kaplan NM. Moderate sodium restriction and various diuretics in the treatment of hypertension. Arch Intern Med 1981; 141:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/49\">",
"      Singer DR, Markandu ND, Sugden AL, et al. Sodium restriction in hypertensive patients treated with a converting enzyme inhibitor and a thiazide. Hypertension 1991; 17:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/50\">",
"      Shahinfar S, Rippley R, Hogg RJ, et al. Multicenter study of enalapril pharmacokinetics in hypertensive children and infants. Pediatr Res 2000; 47:473A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/51\">",
"      Wells T, Frame V, Soffer B, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol 2002; 42:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/52\">",
"      Soffer B, Zhang Z, Miller K, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens 2003; 16:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/53\">",
"      Hogg RJ, Delucchi A, Sakihara G, et al. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr Nephrol 2007; 22:695.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Center for Drug Evaluation and Research. Approved active moieties for which FDA has issued a written request for pediatric studies under Section 3 of the Best Pharmaceuticals for Children Act www.fda.gov/cder/foi/esum/2003/19915s037.pdf (Accessed on November 01, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/55\">",
"      Menon S, Berezny KY, Kilaru R, et al. Racial differences are seen in blood pressure response to fosinopril in hypertensive children. Am Heart J 2006; 152:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/56\">",
"      MacGregor GA, Markandu ND, Singer DR, et al. Moderate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension: a double blind study. Br Med J (Clin Res Ed) 1987; 294:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/57\">",
"      Sakarcan A, Tenney F, Wilson JT, et al. The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol 2001; 41:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/58\">",
"      Shahinfar S, Cano F, Soffer BA, et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens 2005; 18:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/59\">",
"      Flynn JT, Daniels SR. Pharmacologic treatment of hypertension in children and adolescents. J Pediatr 2006; 149:746.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Summaries of medical and clinical pharmacology reviews of pediatric studies www.fda.gov/cder/pediatric/Summaryreview.htm (Accessed on October 05, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/61\">",
"      Herder SD, Weber E, Winkemann A, et al. Efficacy and safety of angiotensin II receptor type 1 antagonists in children and adolescents. Pediatr Nephrol 2010; 25:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/62\">",
"      Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002; 347:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/63\">",
"      Tullus K. Safety concerns of angiotensin II receptor blockers in preschool children. Arch Dis Child 2011; 96:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/64\">",
"      Falkner B, Lowenthal DT, Affrime MB. The pharmacodynamic effectiveness of metoprolol in adolescent hypertension. Pediatr Pharmacol (New York) 1982; 2:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/65\">",
"      Kornbluth A, Frishman WH, Ackerman M. Beta-adrenergic blockade in children. Cardiol Clin 1987; 5:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/66\">",
"      Batisky DL, Sorof JM, Sugg J, et al. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr 2007; 150:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/67\">",
"      Tallian KB, Nahata MC, Turman MA, et al. Efficacy of amlodipine in pediatric patients with hypertension. Pediatr Nephrol 1999; 13:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/68\">",
"      Flynn JT, Smoyer WE, Bunchman TE. Treatment of hypertensive children with amlodipine. Am J Hypertens 2000; 13:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/69\">",
"      Flynn JT, Newburger JW, Daniels SR, et al. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr 2004; 145:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/70\">",
"      Andersen J, Groshong T, Tobias JD. Preliminary experience with amlodipine in the pediatric population. Am J Ther 2006; 13:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/71\">",
"      Flynn JT. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. Pediatr Nephrol 2005; 20:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/72\">",
"      Trachtman H, Frank R, Mahan JD, et al. Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol 2003; 18:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/73\">",
"      Hilgers KF, D&ouml;tsch J, Rascher W, Mann JF. Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both? Pediatr Nephrol 2004; 19:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/74\">",
"      Schmieder RE, Rockstroh JK, Messerli FH. Antihypertensive therapy. To stop or not to stop? JAMA 1991; 265:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/62/27626/abstract/75\">",
"      Course of blood pressure in mild hypertensives after withdrawal of long term antihypertensive treatment. Medical Research Council Working Party on Mild Hypertension. Br Med J (Clin Res Ed) 1986; 293:988.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6131 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-C008A65255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_62_27626=[""].join("\n");
var outline_f26_62_27626=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RATIONALE FOR INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NONPHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Weight reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Sports participation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Salt restriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Potassium intake and the DASH diet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Avoidance of excess alcohol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other CVD risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Whom to treat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antihypertensive drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Thiazide diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - ACE inhibitors/ARBs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MANAGEMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Target blood pressure goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Choice of drug",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Primary hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Drug management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Discontinuation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30228111\">",
"      Therapeutic interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30228125\">",
"      Management approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36868653\">",
"      - Choice of antihypertensive agent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6131\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6131|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/48/18190\" title=\"figure 1\">",
"      BP change and salt intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/24/18829\" title=\"figure 2\">",
"      Antihypertensive dose-response to thiazide therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6131|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/45/7894\" title=\"table 1\">",
"      Normal BP boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/46/7910\" title=\"table 2\">",
"      Normal BP girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/30/13807\" title=\"table 3\">",
"      Antihypertensive drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18068?source=related_link\">",
"      Can therapy be discontinued in well-controlled hypertension?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=related_link\">",
"      Clinical evaluation of the obese child and adolescent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34249?source=related_link\">",
"      Comorbidities and complications of type 2 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40410?source=related_link\">",
"      Complications and screening in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=related_link\">",
"      Diet in the treatment and prevention of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42105?source=related_link\">",
"      Epidemiology, risk factors, and etiology of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2729?source=related_link\">",
"      Evaluation of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=related_link\">",
"      Major side effects and safety of calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=related_link\">",
"      Management of hypertensive emergencies and urgencies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34630?source=related_link\">",
"      Obesity and weight reduction in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21859?source=related_link\">",
"      Ocular effects of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23320?source=related_link\">",
"      Overview of the management of the child at risk for atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/28/38337?source=related_link\">",
"      Patient information: High blood pressure in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/37/30290?source=related_link\">",
"      Patient information: High blood pressure in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/58/931?source=related_link\">",
"      Patient information: High blood pressure treatment in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13060?source=related_link\">",
"      Potassium and hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=related_link\">",
"      Renin-angiotensin system inhibition in the treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=related_link\">",
"      Risk factors and development of atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=related_link\">",
"      Salt intake, salt restriction, and essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=related_link\">",
"      Secondhand smoke exposure: Effects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3395?source=related_link\">",
"      Smoking and hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/13/36058?source=related_link\">",
"      The preparticipation sports examination in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15350?source=related_link\">",
"      Use of thiazide diuretics in patients with primary hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_62_27627="ACMG fragile X screening";
var content_f26_62_27627=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American College of Medical Genetics: Test these populations for fragile X syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Individuals of either sex with mental retardation, developmental delay, or autism, especially if they have:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       physical or behavioral characteristics of fragile X or",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       family history of fragile X or a relative of either sex with undiagnosed mental retardation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Individuals seeking reproductive counseling with",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       family history of fragile X syndrome or",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       family history of undiagnosed mental retardation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fetuses of carrier mothers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Affected individuals or relative in whom the diagnosis was made by cytogenetic studies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Women with elevated levels of follicle-stimulating hormone, especially with a family history of premature ovarian failure, fragile X syndrome, or a relative of either sex with undiagnosed mental retardation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Men or women with late-onset intention tremor or ataxia, especially with a family history of movement disorders, fragile X, or undiagnosed mental retardation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Sherman, S, Pletcher, BA, Driscoll, DA. Fragile X syndrome: diagnostic and carrier testing. Genet Med 2005; 7:584.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_62_27627=[""].join("\n");
var outline_f26_62_27627=null;
var title_f26_62_27628="Spitz conventional histo";
var content_f26_62_27628=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F85843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F85843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histopathologic features of conventional Spitz nevi",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Architecture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diameter &lt;5 to 6 mm*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symmetric outline*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sharp lateral circumscription*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Regular pattern of epidermal hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maturation with dermal depth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zonation across the horizontal axis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wedge-shaped configuration within dermis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orderly nondisruptive infiltration of collagen by melanocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cytology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spindle or epithelioid cell type*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uniform population of cells*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low nuclear to cytoplasmic ratio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opaque or ground glass cytoplasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nuclei with open, delicate chromatin pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uniform nucleoli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rare pleomorphism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other helpful diagnostic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitotic rate &lt;2/mm",
"        <sup>",
"         2",
"        </sup>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absent or rare mitoses in deep dermis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of atypical mitoses*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irregular contours of growth at deep margin*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kamino bodies*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mononuclear or multinucleate giant cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimal central pagetoid upward scatter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Junctional clefts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of cohesion between cells (retraction spaces)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perivascular or diffuse inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Superficial distribution of pigmentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Telangiectasia and edema",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Most helpful features.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted by permission from: Macmillan Publishers Ltd: Modern Pathology. Barnhill RL. The Spitzoid lesion: Rethinking spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment. Mod Pathol 2006; 19 Suppl 2:S21. Copyright &copy; 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_62_27628=[""].join("\n");
var outline_f26_62_27628=null;
var title_f26_62_27629="Initiating Rx 5 to 11 yrs";
var content_f26_62_27629=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classifying asthma severity and initiating treatment in children 5 to 11 years of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"3\">",
"        Components of severity",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Classification of asthma severity (5 to 11 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Intermittent",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"4\">",
"        Persistent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Mild",
"       </td>",
"       <td class=\"subtitle3\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle3\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Impairment",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        &le;2x/month",
"       </td>",
"       <td>",
"        3 to 4x/month",
"       </td>",
"       <td>",
"        &gt;1x/week but not nightly",
"       </td>",
"       <td>",
"        Often 7x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Minor limitation",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung function",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Normal FEV",
"         <sub>",
"          1",
"         </sub>",
"         between exacerbations",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &gt;80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC &gt;85 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &ge;80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC &gt;80 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         = 60 to 80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC = 75 to 80 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &lt;60 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC &lt;75 percent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Risk",
"       </td>",
"       <td rowspan=\"4\">",
"        <strong>",
"         Exacerbations requiring oral systemic glucocorticoids",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0 to 1/year (see footnote)",
"        </strong>",
"       </td>",
"       <td colspan=\"3\">",
"        <strong>",
"         &ge;2/year (see footnote)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Consider severity and interval since last exacerbation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Frequency and severity may fluctuate over time for patients in any severity category",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Relative annual risk of exacerbations may be related to FEV",
"         <sub>",
"          1",
"         </sub>",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"3\">",
"        Recommended step for initiating treatment",
"       </td>",
"       <td rowspan=\"2\">",
"        Step 1",
"       </td>",
"       <td rowspan=\"2\">",
"        Step 2",
"       </td>",
"       <td>",
"        Step 3, medium dose inhaled glucocorticoids option",
"       </td>",
"       <td>",
"        Step 3, medium dose inhaled glucocorticoids option, or step 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        And consider short course of oral systemic glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        In two to six weeks, evaluate level of asthma control that is achieved, and adjust therapy accordingly",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Assessing severity and initiating therapy in children who are not currently taking long-term control medication.",
"    </strong>",
"    The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs. Level of severity is determined by both impairment and risk. Assess impairment domain by patient's/caregiver's recall of the previous two to four weeks and spirometry. Assign severity to the most severe category in which any feature occurs. At present, data are inadequate to correlate frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater underlying disease severity. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic glucocorticoids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.",
"    <div class=\"footnotes\">",
"     EIB: exercise-induced bronchospasm; FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in one second; FVC: forced vital capacity.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_62_27629=[""].join("\n");
var outline_f26_62_27629=null;
var title_f26_62_27630="Causes and evaluation of bronchiectasis in children";
var content_f26_62_27630=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F87712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F87712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes and evaluation of bronchiectasis in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific examples",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic tools",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Congenital bronchiectasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Cartilage deficiency (Williams-Campbell Syndrome)",
"        </p>",
"        Tracheobronchomegaly (Mounier-Kuhn Syndrome)",
"       </td>",
"       <td>",
"        Chest imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Bronchial narrowing/obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital abnormalities",
"       </td>",
"       <td>",
"        <p>",
"         Tracheomalacia, bronchomalacia, tracheal or bronchial stenosis, bronchogenic cyst, tracheal bronchus, vascular ring, pulmonary artery aneurysm, or dilation",
"        </p>",
"        <p>",
"         Bronchopulmonary sequestration (intralobar)",
"        </p>",
"        Congenital pulmonary airway (cystic adenomatoid) malformation (CPAM or CCAM)",
"       </td>",
"       <td>",
"        <p>",
"         Chest imaging (CT scan with angiogram) &ndash; to evaluate for sequestration, CPAM, vascular rings, or pulmonary artery abnormalities",
"        </p>",
"        Flexible bronchoscopy &ndash; to evaluate for bronchomalacia, ectopic bronchus, bronchial stenosis, or vascular compression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Foreign body aspiration",
"       </td>",
"       <td>",
"        Peanuts, candy, small objects",
"       </td>",
"       <td>",
"        History (eg, of choking episode, even if remote, and/or recurrent pneumonia), physical exam, chest imaging, and rigid bronchoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mucoid impaction",
"       </td>",
"       <td>",
"        <p>",
"         Mucus plug (post operative, asthma, middle lobe syndrome)",
"        </p>",
"        <p>",
"         Allergic bronchopulmonary aspergillosis (ABPA)",
"        </p>",
"        Bronchocentric granulomatosis (BG)",
"       </td>",
"       <td>",
"        Chest imaging, serology for Aspergillus, IgE, flexible bronchoscopy with BAL, and biopsy in case of BG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hilar adenopathy",
"       </td>",
"       <td>",
"        <p>",
"         Tuberculosis",
"        </p>",
"        <p>",
"         Histoplasmosis",
"        </p>",
"        Sarcoidosis",
"       </td>",
"       <td>",
"        Chest imaging, flexible bronchoscopy, serology, cultures, and biopsy if needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tumors",
"       </td>",
"       <td>",
"        Airway adenoma, endobronchial teratoma",
"       </td>",
"       <td>",
"        Chest imaging, flexible bronchoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Immunodeficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immunoglobulin deficiencies",
"       </td>",
"       <td>",
"        <p>",
"         Congenital agammaglobulinemia (Bruton's disease)",
"        </p>",
"        <p>",
"         Selective IgG subclass deficiency (IgG2, IgG4)",
"        </p>",
"        <p>",
"         Common variable immunodeficiency",
"        </p>",
"        <p>",
"         IgA deficiency with ataxia-telangiectasia",
"        </p>",
"        Selective IgA deficiency (possible association)",
"       </td>",
"       <td>",
"        Quantitative immunoglobulin levels, immunoglobulin subclasses, humoral panel with specific antibody titers to childhood vaccines and pneumococcal vaccine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leukocyte dysfunction",
"       </td>",
"       <td>",
"        Chronic granulomatous disease (NADPH oxidase dysfunction)",
"       </td>",
"       <td>",
"        Dihydrorhodamine 123 (DHR) test; Nitroblue tetrazolium test, genetic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Combined immunodeficiencies",
"       </td>",
"       <td>",
"        <p>",
"         Severe combined immunodeficiency",
"        </p>",
"        <p>",
"         DiGeorge syndrome",
"        </p>",
"        <p>",
"         Bare lymphocyte syndrome (T cell receptor defect caused by major histocompatibility complex [MHC] deficiency)",
"        </p>",
"        <p>",
"         CXCR4 mutation (WHIM syndrome)",
"        </p>",
"        <p>",
"         CD40 deficiency or CD40 ligand deficiency (hypergammaglobulinemia M syndrome)",
"        </p>",
"        Others",
"       </td>",
"       <td>",
"        Chest x-ray, immunoglobulin levels, specific antibody titers, evaluation of lymphocyte subsets (T, B, and NK), and assessment of T cell function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complement deficiency",
"       </td>",
"       <td>",
"        eg, C3 deficiency, Ficolin-3 deficiency",
"       </td>",
"       <td>",
"        Complement assays (C3, C4, and THC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acquired immunodeficiencies",
"       </td>",
"       <td>",
"        Pharmacologic immunosuppression, HIV infection, malnutrition, malignancy, etc",
"       </td>",
"       <td>",
"        History, blood counts, quantitative immunoglobulins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Abnormal secretion clearance (leading to chronic airway infection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abnormal secretions",
"       </td>",
"       <td>",
"        Cystic fibrosis",
"       </td>",
"       <td>",
"        Sweat test, genetic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ciliary dysfunction",
"       </td>",
"       <td>",
"        Primary ciliary dyskinesia (known as Kartagener syndrome if situs inversus is present)",
"       </td>",
"       <td>",
"        <p>",
"         Nasal or bronchial ciliary biopsy with motility studies, and electron microscopy, genetic testing",
"        </p>",
"        Situs inversus in Kartagener syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unknown mechanism",
"       </td>",
"       <td>",
"        Young syndrome (obstructive azoospermia and sinopulmonary disease)",
"       </td>",
"       <td>",
"        Sperm count",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other causes",
"       </td>",
"       <td>",
"        CNS abnormalities, muscle weakness, and weak cough",
"       </td>",
"       <td>",
"        History and exam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Persistent bacterial bronchitis",
"       </td>",
"       <td>",
"        Varied organisms",
"       </td>",
"       <td>",
"        History of chronic wet cough, sputum culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacterial pneumonia",
"       </td>",
"       <td>",
"        Staphylococcus aureus, Streptococcus pneumonia, Klebsiella, Pseudomonas aeruginosa",
"       </td>",
"       <td>",
"        History and cultures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Childhood infection",
"       </td>",
"       <td>",
"        eg, pertussis, measles",
"       </td>",
"       <td>",
"        History of infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Viral infections",
"       </td>",
"       <td>",
"        Adenovirus (particularly types 7 and 21), influenza, herpes simplex",
"       </td>",
"       <td>",
"        History, viral studies (titers, PCR, culture)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other infections",
"       </td>",
"       <td>",
"        <p>",
"         Fungal (histoplasmosis)",
"        </p>",
"        <p>",
"         Mycobacterium tuberculosis, atypical mycobacterium",
"        </p>",
"        Possibly mycoplasma",
"       </td>",
"       <td>",
"        History, serology, cultures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recurrent aspiration",
"       </td>",
"       <td>",
"        <p>",
"         Neurological disorders",
"        </p>",
"        <p>",
"         Vocal cord paralysis",
"        </p>",
"        <p>",
"         Swallowing dysfunction",
"        </p>",
"        <p>",
"         Laryngeal clefts",
"        </p>",
"        <p>",
"         Tracheoesophageal fistula",
"        </p>",
"        Gastroesophageal reflux disease",
"       </td>",
"       <td>",
"        <p>",
"         History, chest imaging",
"        </p>",
"        <p>",
"         Swallowing studies and contrast esophagram",
"        </p>",
"        Direct laryngoscopy with probing for laryngeal cleft",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Miscellaneous disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bronchiolitis obliterans",
"       </td>",
"       <td>",
"        <p>",
"         Post infectious",
"        </p>",
"        <p>",
"         Post transplant with chronic rejection (Bone marrow, lung transplant)",
"        </p>",
"        <p>",
"         Interstitial lung disease",
"        </p>",
"        Other causes",
"       </td>",
"       <td>",
"        History, PFTs, Chest CT scan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Genetic disorders",
"       </td>",
"       <td>",
"        Yellow nail syndrome&nbsp;(MIM %153300): yellow nails, lymphedema, and respiratory tract disease with pleural effusions",
"       </td>",
"       <td>",
"        Physical examination, family history, possible genetic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autoimmune and connective tissue disease",
"       </td>",
"       <td>",
"        <p>",
"         Rheumatoid arthritis",
"        </p>",
"        <p>",
"         Scleroderma",
"        </p>",
"        <p>",
"         Relapsing polychondritis (RP)",
"        </p>",
"        <p>",
"         Tracheobronchial amyloidosis",
"        </p>",
"        Marfan syndrome",
"       </td>",
"       <td>",
"        <p>",
"         History, physical exam",
"        </p>",
"        <p>",
"         Rheumatological work up",
"        </p>",
"        <p>",
"         Cartilage biopsy for RP",
"        </p>",
"        Biopsy for amyloid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inhalation of toxic fumes and dusts",
"       </td>",
"       <td>",
"        <p>",
"         Ammonia",
"        </p>",
"        <p>",
"         Nitrogen dioxide",
"        </p>",
"        <p>",
"         Other irritant gases",
"        </p>",
"        <p>",
"         Smoke",
"        </p>",
"        <p>",
"         Talc",
"        </p>",
"        Silicate",
"       </td>",
"       <td>",
"        <p>",
"         Exposure history",
"        </p>",
"        Chest imaging",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computerized tomography; BAL: bronchoalveolar lavage; WHIM: warts, hypogammaglobulinemia, infections, and myelokathexis; THC: total hemolytic complement (CH50); CNS: central nervous system; PCR: polymerase chain reaction; PFTs: pulmonary function tests; MIM: Mendelian Inheritance in Man (also known as OMIM)&nbsp;database.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Khoulood Fakhoury, MD, and Adaobi Kanu, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_62_27630=[""].join("\n");
var outline_f26_62_27630=null;
var title_f26_62_27631="Band snare cartoon";
var content_f26_62_27631=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cartoon depicting the band and snare technique for endoscopic mucosal resection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lesion (A) is raised with a submucosal injection (B). The banding hood is used to deploy a band ligation (C), which encapsulates the lesion (D).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher Gostout, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_62_27631=[""].join("\n");
var outline_f26_62_27631=null;
